{
  "Article 1: Inter-Limb Strength Asymmetry": "\n--- PAGE 1 ---\nORIGINAL RESEARCH ARTICLE\nInter-Limb Strength Asymmetry and Risk of\nTotal Knee Replacement\nA Survival Analysis\nCarsonHalliwell,PhD,1,2,3SophieRayner,Bsc,1JanieAstephenWilson,PhD,4DerekRutherford,PT,PhD,1,4\nBrettFeltmate,Msc,5HeatherNeyedli,PhD,5andRebeccaMoyer,PT,PhD1\nObjective:Thecurrentstudyexploredtheassociationbetweenknee\nWhatIsKnown\nextensor strength asymmetry and the risk of total knee arthroplasty\ninindividualswithoratriskofkneeosteoarthritis. (cid:129) Kneeextensorstrengthisaknownpredictorofknee\nDesign:ThislongitudinalcohortstudyanalyzeddatafromtheOsteo- osteoarthritisonsetandprogression.\narthritisInitiative,including3860individualswithoratriskforkneeos- WhatIsNew\nteoarthritis.Participantswerecategorizedashavingsymmetricalorasym-\n(cid:129) Individuals with a greater than 10% discrepancy in\nmetricalkneeextensorstrengthbasedona10%differencebetweenlimbs.\nkneeextensorstrengthbetweenlimbsmaybeatan\nKaplan-MeiercurvesandCoxregressionassessedtheriskoftotalknee\nincreasedriskoftotalkneearthroplastyover10yrsre-\narthroplastyover10yrs,adjustingforage,sex,bodymassindex,baseline\ngardless of both symptomatic and radiographic se-\nKellgren-Lawrencegrade,absoluteweakness,andbaselinepain.\nverity.This10%discrepancybetweenkneeextensor\nResults:Participantswithasymmetricalkneeextensorstrengthhada\nstrengthshouldbeconsideredwheninformingtreat-\n30%greaterriskofundergoingtotalkneearthroplastyover10yrscom-\nmentandrehabilitativeoutcomes.\nparedtothosewithsymmetricalstrength(hazard-ratio:1.30,95%CI\n[1.05,1.62]).Limb-specificanalysesrevealedthata10%reductionin\nrightandleftkneeextensorstrengthwereassociatedwitha40%and\n80%increasedriskofrightandlefttotalkneearthroplasty,respectively. vidualsworldwidewithprevalencesteadilyincreasing,posing\nConclusions:Kneeextensorstrengthasymmetrywasassociatedwith\naglobalhealthchallenge.2Commontreatmentmodalitiespri-\ntheriskoftotalkneearthroplastyinindividualswithoratriskforknee marilyaimtomanagesymptoms,oftenculminatinginsurgical\nosteoarthritis.Findingssupporttheneedtofurtherexamineifaninter- interventionthroughtotalkneearthroplasty(TKA).3Thenum-\nventiontargetedatquadricepsstrengtheningaimedatachievingand berofTKAsperformedannuallyisgrowingexponentially,and\nmaintainingstrengthsymmetrycanreducetotalkneearthroplastyrisk. places a significant financial burden on healthcare systems,\nwith an estimated $10 billion spent annually on OA in\nKeyWords:KneeOsteoarthritis,TotalKneeArthroplasty, Canada alone.4 After the COVID-19 pandemic, wait times\nKneeExtensorStrength,Symmetry\nforTKAsurgerieshaveincreased,withthenumberofsurgeries\n(AmJPhysMedRehabil2025;104:1133–1139) performedwithinthe nationalbenchmark of182daysfalling\nfrom72%to59%.5KneeOAhasmanyknownmodifiablerisk\nfactors which influence the development and progression of\nthe disease such as obesity, joint injury, physical inactivity,\nKnee osteoarthritis (OA) is a debilitating and progressive and reduced muscle strength.6 To reduce the burden of knee\njointdiseasecharacterizedbychronicpainandfunctional\nOAonindividualsandonhealthcaresystems,abetterunder-\ndecline.1KneeOAisestimatedtoaffectover350millionindi-\nstandingofhowthesemodifiableriskfactorsinfluencethepro-\ngressionofthediseaseshouldbeinvestigated.\nNotably, reduced knee extensor strength plays a crucial\nFromthe1SchoolofPhysiotherapy,DalhousieUniversity,Halifax,Canada;2Department\nrole in both the development and progression of knee OA,\nofMedicine,UniversitédeSherbrooke,Sherbrooke,Canada;3CentredeFormation\nMédicaleduNouveau-Brunswick,Moncton,Canada;4SchoolofBiomedical makingitakeytargetforinterventions.7,8Therelationshipbe-\nEngineering, Dalhousie University, Halifax, Canada; and 5School of Health tweenkneeOAandreducedkneeextensorstrengthiscomplex.\nandHumanPerformance,DalhousieUniversity,Halifax,Canada.\nWhilereducedstrengthhasbeenassociatedwiththeonsetof\nAllcorrespondenceshouldbeaddressedto:RebeccaMoyer,PT,PhD,Dalhousie\nUniversity,5869UniversityAve,Halifax,NSB3H4R2. knee OA,7,8 muscle atrophy and weakness often accompany\nCarsonHalliwell,SophieRaynerandBrettFeltmateareintraining. thediseaseprocess.9Kneeextensorweaknessisoftenpresent\nFunding:CarsonHalliwellwassupportedbyArthritisSocietyCanada’sPhDSalary\nAward22-0000000152 inearlykneeOAbeforepainonset,suggestingmusclestrength\nDetailsofanypreviouspresentationoftheresearch,manuscript,orabstract:Portions asapotentialprimaryriskfactorforkneeOAdevelopment.10\nofthedatawerepresentedattheCanadianOrthopedicAssociationannual\nThekneeextensorsplayacrucialroleinstabilizingandatten-\nmeetingonJune13th,2024.\nDatasharingstatement:Allrawdataareavailableinapublic,openaccessrepository. uatingloadthroughthekneeduringwalking11posingapoten-\nOsteoarthritisInitiative,https://nda.nih.gov/oai tialmechanismwherekneeextensorweaknessmayleadtoal-\nFinancialdisclosurestatementshavebeenobtained,andnoconflictsofinteresthave\nteredjointloading,therebyacceleratingstructuraldeterioration.7\nbeenreportedbytheauthorsorbyanyindividualsincontrolofthecontentof\nthisarticle. Reducedkneeextensorstrengthhasalsobeenfoundtobeasso-\nCopyright©2025WoltersKluwerHealth,Inc.Allrightsreserved. ciatedwithsymptomatickneeOAprogression,andfunctional\nISSN:0894-9115\nDOI:10.1097/PHM.0000000000002775\ndeclineinthechair-standtest.8\nAmericanJournalofPhysicalMedicine&Rehabilitation (cid:129) Volume104,Number12,December2025 www.ajpmr.com 1133\n\n--- PAGE 2 ---\nHalliwelletal. Volume104,Number12,December2025\nAlthoughmostresearchhasfocusedontheaffectedknee, Pain Rating Scale (NPRS). This study conforms to the\nfew studies have investigated how inter-limb differences in StrengtheningtheReportingofObservationalStudiesinEpi-\nkneeextensorstrengthinfluencekneeOAprogression.Previ- demiology(STROBE)guidelinesandreportstherequiredin-\nous researchexaminingkneeextensor strengthasymmetryin formationaccordingly(seeSupplementaryChecklist).Ethical\nindividuals postanteriorcruciate ligament(ACL) reconstruc- approvalandinformedconsentwereobtainedasapartofthe\ntionhasshownthatindividualswhohadasymmetricalkneeex- original study. The Nova Scotia Health Authority Research\ntensorstrengthafterACLrepairhadelevatedaffectedkneeT2 Ethics Board does not review research involving secondary\nrelaxation times (indicating compositional cartilage changes analyses of datasets that contain deidentified individual-level\nandpossible early jointdegeneration)5 yrs after ACLrecon- data,suchastheOsteoarthritisInitiative.\nstructioncomparedtothosewhohadsymmetricalkneeexten-\nsorstrength.12Additionally,every1%increaseinkneeexten- MaximumIsometricKneeStrength\nsor symmetry has been shown to reduce the risk of clinical KneeextensorstrengthwasmeasuredusingaGoodStrength\nkneeOAdevelopment,definedas≤85/100in2of4Kneein- isometricstrengthchair(Metitur,Jyvaskyla,Finland)16withpar-\njury and Osteoarthritis Outcome Score (KOOS) subscales ticipantsseatedandtheirkneepositionedat60degreesofflexion.\n(pain,symptoms,activitiesofdailyliving,knee-relatedquality The load cell was positioned approximately 2 cm above the\noflife)atthe5-yrfollow-up.13Giventheimportanceofknee\ncalcaneus. Participants were given two 50% warm-up trials\nextensorstrengthinthecontextofkneeOA,itiscrucialtoex- fortrialfamiliarizationbeforethree100%measurementtrials.\nplorewhetherasymmetryinthisstrengthnotonlyaffectsjoint Thehighestvaluecalculatedfromthethreemeasurementtrials\nhealthpost-ACLreconstructionbutalsoplaysaroleintheclin- for knee extension was used for maximal isometric strength\nicalprogressionofkneeOAlaterinthediseaseprocess,partic- (Newtons). All maximum strength testing was performed at\nularlyconcerningprogressiontoTKA. baseline(OAIV00timepoint)andvalueswerenormalizedto\nDespite these findings, the impact of knee extensor bodymass(N/kg).\nstrength asymmetry on the progression of knee OA, particu-\nlarlyinrelationtotheneedforTKA,remainsunderexplored.\nDataProcessing\nTherefore, the current study aimed to explore the association\nTocaptureabsolutemuscleweaknessrelativetoclinically\nbetween knee extensor strength asymmetry and the risk of\nsimilarpeers,participantswerestratifiedinto24groupsbased\nprogressingtoTKAinindividualswithoratriskofkneeOA.\non sex (male or female), Kellgren-Lawrence grade severity\n(no-mild [KLG 0–1] vs. moderate-to-severe [KLG 2–4]),17\nMETHODS painseverity(NumericPainRatingScalescore<2vs.≥2),18\nand age tertiles (ages; 45–56, 57–66, 67–79). For instance, one\nParticipants\ngroupincludedfemalesinthemiddleagetertile(e.g.,45–56yrs)\nwith moderate to severe radiographic knee osteoarthritis and\nAllparticipantswereselectedfromtheOsteoarthritisIni-\nclinicallymeaningfulpain(painscore≥2).Withineachgroup\ntiative, a multicenter, longitudinal, publicly available cohort\n(n = 82–280), mean and standard deviation (SD) values for\nstudywiththegoalofimprovingpublichealththroughthepre-\nventionandalleviationofpainanddisabilityfromkneeOA.14 strength were calculated. Absolute weakness was defined as\nastrengthvaluemorethanoneSDbelowthegroupmean.\nThe Osteoarthritis Initiative includes 4796 individuals aged\n45–79atbaseline,withoratriskfordeveloping tibiofemoral Absolutestrengthsymmetry indices(SI)werecalculated\nfor knee extensor strength at baseline (OAI V00 timepoint)\nkneeOA.Inclusioncriteriaandmethods oftheOsteoarthritis\nInitiative have been described in detail previously.14 Partici- usingtheformula∥((X R −X L )/(0.5(X R +X L ))∗100)∥.19Avalue\nofzeroindicatedperfectsymmetrybetweenknees,andhigher\npantsinthecurrentstudywererequiredtohavebeenenrolled\nvaluesrepresentedgreaterasymmetry.Acutoffvalueof±10%\nin the study at baseline (OAI V00 timepoint) and have been\nwassettoindicateasymmetrybetweenlimbs,withinter-limb\nfollowedforthedurationoftheoriginalOAIcohort(120mos),\nstrength SI values >10% considered asymmetrical, and SI\nhave full knee extensor strength data from both lower limbs,\nKellgren-Lawrencegrade(KLG)15inbothknees,responseto\nvalues<10%consideredsymmetrical.20Limb-specificSIwere\nalsocalculatedwithouttakingtheabsolutevalue,whereapos-\nseverityofkneepainexperiencedoverthepast30-daysatbase-\nitivevalueindicatedthatthemagnitudewasgreaterontheright\nline(OAIV00timepoint),andhavedataindicatingwhetherthe\nside(SI>10%),anegativevalueindicatedthatthemagnitude\nparticipants have had a follow-up knee replacement and the\nwasgreaterontheleftside(SI<−10%),andSIvaluesbetween\ntimingofsurgeryfrombaselinedatacollection(n=3860).If\n−10%and10%wereconsideredsymmetrical.\naparticipantwasnotenrolledatbaseline(OAIV00timepoint)\ntheywerenotaddedtotheanalysisiftheywereenrolledata\nlater timepoint.Ifparticipantsreportedhavinghadakneere- StatisticalAnalyses\nplacement,theywereputintoanadjudicationprocess,where Student t tests were performed to determine between\nthe procedure was confirmed through medical records or an groupdifferencesinparticipantdemographicsandcharacteris-\nx-ray.ForindividualswhohadbilateralTKAoverthestudype- tics.Therelationshipbetweenbaselinekneeextensorstrength\nriod,onlythefirstsurgicalkneewasusedintheanalyses.All symmetry status and longitudinal TKA treatment was exam-\nTKA’s recorded were performed after initial enrollment into inedusingKaplan-Meiercurves,withsurvivalevaluatedbased\nthe OAI and baseline knee extensor strength measurements. ontheMantel-Coxlog-ranktest.21Unadjusted(uHRs)andad-\nAllparticipantswereaskedtoranktheirkneepainintensityex- justed(aHRs)hazardratioswerecalculatedusingmultivariable\nperienced over the past 30-days using an 11-point Numeric Cox regression models to determine the risk of TKA in\n1134\nwww.ajpmr.com ©2025WoltersKluwerHealth,Inc.Allrightsreserved.\n\n--- PAGE 3 ---\nVolume104,Number12,December2025 StrengthAsymmetryandTKA:ASurvivalAnalysis\nsymmetricalversusasymmetricalparticipants.Adjustedmodels acrosssymmetrystatuswassignificantlydifferent(P<0.001)\nincludedvariablespreviouslyassociatedwithkneeOAprogres- (Fig.1).Nosignificantinteractionbetweenstrengthasymmetry\nsion including baseline age, sex, baseline body mass index andabsoluteweaknesswasobserved(P>0.05),indicatingthat\n(BMI), baseline KLG, absolute weakness, and baseline pain.6 therelationbetweenasymmetryandTKAriskdidnotdifferbased\nToevaluatewhetherabsoluteweaknessmodifiedtherelationbe- onabsoluteweaknessstatus.Comparedtoparticipantswith sym-\ntweenstrengthasymmetryandriskofTKA,aninteractionterm metrical strength, adjusted models indicated that participantswith\nbetweenasymmetryandabsoluteweaknesswasalsocreatedand asymmetry were at a 30% higher risk of undergoing TKA over\ntested in all models. Limb-specific uHRs and aHRswere also 10 yrs (uHR: 1.41, 95% CI [1.15,1.74]; aHR: 1.30, 95%CI\ncalculated to assess the risk of right and left TKA separately. [1.05,1.62])(Fig.1).Additionalvariablesthatsignificantlypredicted\nAnalphalevelof0.05wassettodetectsignificanceforallsta- timetoTKAwerehigherbaselinerightKLG(aHR:1.91,95%CI\ntistical tests. Statistical analyses were completed using SPSS [1.72,2.13]), left KLG (aHR: 1.63, 95%CI [1.46,1.81]),and\n(Version28.0,IBMCorp.,Armonk,NY). higherbaselineleftkneepain(aHR:1.07,95%CI[1.03,1.11]).\nAdetaileddescriptionofaHRand95%CIsforallpredictorvar-\nRESULTS iablesincludedwithinthemodelarepresentedinFigure1.\nParticipantCharacteristics RiskforRightTotalKneeArthroplasty\nParticipantdemographicsandcharacteristicsarepresentedin When assessing limb specific models and time to right\nTable1.Atotalof3860individualswereincludedinthisstudy, TKA, log-rank tests indicated that the distribution of TKAs\nand1615(41.8%)weredeemedtohavesymmetricalkneeexten- acrosssymmetrystatuswassignificantlydifferent(P<0.001)\nsorstrengthwhile2245(58.2%)hadasymmetricalkneeextensor (Fig. 2). Compared to participants with symmetrical strength,\nstrength.Oftheasymmetricalgroup,atotalof1628individuals adjusted models indicated that individuals with right less-than\n(72%)hadrightgreaterthanleftkneeextensorstrengthand617 leftkneeextensorstrengthwereata40%increasedriskofun-\nindividuals (28%) had left greater than right knee extensor dergoing right TKA over 10 yrs (uHR: 2.14, 95% CI\nstrength. There were no differences in age (P = 0.23), BMI [1.53,2.98];aHR:1.40,95%CI[1.12,1.77])(Fig.2).Additional\n(P=0.24),distributionofmalesandfemales(P=0.18),orright variables that significantly predicted time to right TKA were\nkneepain(P=0.15).Individualswithasymmetricalkneeexten- baseline higher right KLG (aHR: 2.94, 95%CI [2.50,3.46]),\nsorstrengthwerefoundtohaveahigherincidenceofreceiving andhigher rightkneepain(aHR:1.12,95%CI[1.06,1.19]).A\nTKA(P=0.001),worseleftkneepainatbaseline(P=0.010), detaileddescriptionofaHRand95%CIsforallpredictorvari-\ngreaterkneeextensorstrengthasymmetry(P=0.001)andlower ablesincludedwithinthemodelarepresentedinFigure2.\nrightandleftkneeextensorstrength(P=0.001)comparedtoin-\ndividualswith symmetrical knee extensor strength at baseline. RiskforLeftTotalKneeArthroplasty\nIndividualswithasymmetricalkneeextensorstrengthalsohad WhenassessinglimbspecificmodelsandtimetoleftTKA,\ngreaterrightkneestrengthcomparedtoleft(P=0.001). log-ranktestsindicatedthatthedistributionofTKAsacrosssym-\nmetrystatuswassignificantlydifferent(P<0.001)(Fig.3).Com-\nRiskforTotalKneeArthroplasty paredtoparticipantswithsymmetricalstrength,adjustedmodels\nWhenassessingabsolutestrengthasymmetryandtimeto indicated thatindividualswithleftless-than right kneeextensor\nTKA, log-rank tests indicated that the distribution of TKAs strength were at a 80% increased risk of undergoing left TKA\nTABLE1. Baselineparticipantdemographicsandclinicalcharacteristics\nSymmetrical(n=1615) Asymmetrical(n=2245)\nAge(yrs) 62±9.0 61±9.0 0.23\nSex,no.females(%) 904(56) 1302(58) 0.18\nBMI(kg/m2) 28.5±4.55 28.7±4.87 0.24\nTKA,no.(%)a 127(7) 246(11) <0.01\nTimetoTKA(yrs) 4.95(2.34) 5.02(2.39) 0.77\nRightKLG,median(IQR) 1(0–2) 1(0–2) -\nLeftKLG,median(IQR) 1(0–2) 1(0–2) -\nRightkneeNPRS(0–10) 2.59±2.63 2.72±2.73 0.11\nRightkneepain,no.NPRS>1(%) 833(55) 1230(54) 0.80\nLeftkneeNPRS(0–10) 2.30±2.63 2.83±2.81 <0.01\nLeftkneepain,no.NPRS>1(%) 769(48) 1256(56) <0.01\nKneeextensorstrengthsymmetry(%) 4.73±2.89 25.1±16.4 <0.01\nRightkneeextensorstrength(N/kg) 4.53±1.43 4.30±1.52b <0.01\nLeftkneeextensorstrength(N/kg) 4.49±1.41 3.84±1.44b <0.01\nValuesarelistedasmeanandstandarddeviationunlessotherwiseindicated.\naRepresentsthenumberofTKAsperformedoverthedurationofthestudyafterbaselineenrollment.\nbIndicatesstatisticaldifferencewithingroups(P<0.01).\n1135\n©2025WoltersKluwerHealth,Inc.Allrightsreserved. www.ajpmr.com\n\n--- PAGE 4 ---\nHalliwelletal. Volume104,Number12,December2025\nFIGURE1. A,Kaplan-MeiersurvivalplotsforkneeextensorstrengthsymmetryontimetoTKA.Symmetric(absoluteSI<10%)group(dottedline)and\nasymmetric(absoluteSI>10%)group(solidline).B,ForestplotillustratingtheaHRsand95%CIsforthelikelihoodprogressing(increasedaHR)ornot\nprogressing(decreasedaHR)tototalkneearthroplastyover10yrs.\nover10yrs(uHR:2.12,95%CI[1.52,2.99];aHR:1.80,95%CI [1.06,1.43])andleft(aHR:2.74,95%CI[2.31,3.25])KLG,right\n[1.26,2.59]) (Fig. 3). Additional variables that significantly pre- (aHR: 0.94, 95%CI [0.88,0.99]) and left (aHR: 1.12, 95%CI\ndictedtimetoleftTKAwerebaselineright(aHR:1.23,95%CI [1.05,1.18])kneepain.AdetaileddescriptionofaHRand95%\nFIGURE2. A,Kaplan-MeiersurvivalplotsforkneeextensorstrengthsymmetryontimetorightlimbTKA.Symmetric(SI-10:10%)group(dottedline),\nleftgreater-thanrightasymmetric(SI<10%)group(dashedline),andrightgreater-thanleftasymmetric(SI>10%)group(solidline).B,Forestplot\nillustratingtheaHRsand95%CIsforthelikelihoodprogressing(increasedaHR)ornotprogressing(decreasedaHR)torightlimbtotalknee\narthroplastyover10yrs.\n1136\nwww.ajpmr.com ©2025WoltersKluwerHealth,Inc.Allrightsreserved.\n\n--- PAGE 5 ---\nVolume104,Number12,December2025 StrengthAsymmetryandTKA:ASurvivalAnalysis\nFIGURE3. A,Kaplan-MeiersurvivalplotsforkneeextensorstrengthsymmetryontimetoleftlimbTKA.Symmetric(SI-10:10%)group(dottedline),\nleftgreater-thanrightasymmetric(SI<10%)group(dashedline),andrightgreater-thanleftasymmetric(SI>10%)group(solidline).B,Forestplot\nillustratingtheaHRsand95%CIsforthelikelihoodprogressing(increasedaHR)ornotprogressing(decreasedaHR)toleftlimbtotalkneearthroplasty\nover10yrs.\nCIsforallpredictorvariablesincludedwithinthemodelarepre- asthepassivestructuresdeteriorate.23AskneeOAprogresses,\nsentedinFigure3. thepassivesubsystembecomesprogressivelymoredamaged,\nandinresponsetheactivesubsystemmusttakeonalargerrole\nDISCUSSION to maintain joint stability. This neuromuscular compensation\nThis study aimed to determine whether knee extensor has been shown in multiple studies demonstrating increased\nstrength asymmetry was associated with an increased risk of andprolongedactivationofthekneeextensorsduringwalking,\nTKAinindividualswithoratriskforkneeOAusingdatafrom thought to be an attempt to create a natural brace for the\nthe Osteoarthritis Initiative. Results demonstrated that after joint.24,25 The increased and prolonged knee extensor activa-\ncontrolling for age, sex, BMI, baseline KLG, absoluteweak- tionmayincreasetheforcesactingthroughthejoint,whilealso\nness, and baseline pain, individuals with asymmetrical knee leading to more consistent loading.24,25 In this context, the\nextensor strength was associated with a 30% greater risk of study suggests that when greater than a 10% discrepancy in\nTKA over 10 yrs compared to individuals with symmetrical kneeextensorstrengthispresent,theweakerkneemaynotad-\nknee extensor strength. Further, limb specific analyses re- equately compensate for passive subsystem deterioration,\nvealedthatcomparedtoindividualswithsymmetricalkneeex- resultinginfaster progressiontoTKA;however,thiswasnot\ntensor strength, individuals with reduced knee extensor directlymeasuredinthecurrentstudy.\nstrengthintheirrightlimbhada40%greaterriskofrightlimb Previous research has demonstrated that knee extensor\nTKA,whileindividualswithreducedkneeextensorstrengthin strengthasymmetryisassociatedwithworsekneeOA-related\ntheirleftlimbhada80%greaterriskofleftlimbTKAover10 painandimagingbiomarkerspost-ACLrepair.12,13Thecurrent\nyrs.Theseresultsbuilduponpreviousresearchlinkingreduced study extends these findings by revealing that a greater than\nknee extensor strength with symptomatic and radiographic 10% strength discrepancy between knees is associated with\nkneeOAprogressionbyusingTKAastheclinicalendpoint. anincreasedrisktoprogresstoTKA.This10%cutoffmayof-\nThe results of the current study build on previous work fercliniciansacriterionvalueinwhichpotentialtargetedinter-\nshowingthatreducedkneeextensorstrengthisassociatedwith ventionshouldtakeplace.Importantly,thefindingsofthecur-\nsymptomaticandradiographickneeOAprogression,7,8byex- rentstudydisplayassociationsbetweenkneeextensorstrength\naminingkneeextensorstrengthasymmetryandusingTKAas asymmetry and risk to TKA. Future studies should assess\ntheclinicalendpointofthedisease.Higherlevelsofkneeex- whether symmetry-focused strength training reduces TKA\ntensorstrengthasymmetrymayindicatedecreasedkneeexten- risk, aligning with best practice guidelines that recommend\nsorstrength,leadingtochangesinquadricepsactivationsdur- strengtheningexercisestorestorefunctionandalleviatepain.26\ningwalking,whichhavebeenshowntobepredictiveofTKA Future research assessing causal relationships, including\ninpreviouswork.22AccordingtoPanjabi’sstabilizationmodel, whethersymmetry-focusedstrengthtraininginterventionslead\nreducedmusclestrengthdisruptsthebalanceamongtheneu- to a reduced risk of TKA in individuals with/at risk of knee\nral,passive,andactivesubsystems,leadingtojointinstability OA,isneeded.\n1137\n©2025WoltersKluwerHealth,Inc.Allrightsreserved. www.ajpmr.com\n\n--- PAGE 6 ---\nHalliwelletal. Volume104,Number12,December2025\nThe strongest predictor of time to TKAwas found tobe strength discrepancy between knees may result in an uneven\ndiseaseseverityusingtheKLG;however,withthecurrentre- distribution of load, increasing stress on the weakened knee\nports suggesting a shift away from routine imaging for knee and leading to inefficient movement patterns. Arthrogenic\nOAdiagnosisanddiseasetracking,27thismeasuremaynotbest muscular inhibition may further contribute to this imbalance\nalign with current management practices. The current study bylimitingvoluntaryquadricepsactivationintheweakerlimb,\nprovides preliminary evidence that examining knee extensor exacerbatingasymmetryovertime.Chronicarthrogenicmus-\nstrength asymmetry may be a useful clinical measure for cular inhibition, driven by joint pain and structural damage,\nassessingriskofTKAandmayallowforearly,targetedinter- could accelerate muscleweakness and functional decline, in-\nventions aimed at delaying the time to TKA. Although our creasingthelikelihoodofsurgicalintervention.Overtime,this\nstudy focused primarilyon objective measures, patient-reported imbalancemayworsenphysicalfunction,increasingtheriskof\noutcomessuchastheKOOS28providevaluableinsightinto falls,injury,andlossofindependence,astheweakerkneemay\nhowindividualsperceivetheirsymptoms,function,andquality be unable to provide adequate support during key activities.\noflife.Previousresearchhasshownthatgreaterkneeextensor Therefore, minimizing strength asymmetry between knees\nstrengthasymmetryisassociatedwithworseKOOSscores,13 may be an important measure for maintaining functional ca-\nindicatingalinkbetweenasymmetryandpatient-reportedout- pacityandpreservingindependenceforolderadults.\ncomes.Thesesubjectivemeasuresareimportantinsurgicalde-\ncision-making, as they capture patient perspectives that may Limitations\nnotbefullyreflectedinstrengthasymmetryorradiographicse- Thecurrentstudy’sstrengthsincludeitslargesamplesize,\nverity alone. While we did not analyze patient-reported out- longitudinaldesign, and the use ofwell-establishedmeasures\ncomesinthisstudy,futureresearchintegratingthesemeasures ofkneestrengthandOAprogression.15However,therearelim-\nwith objective assessments could enhance our understanding itationstoconsider.Notably,onlyquadricepsmusclestrength\nofthe factors driving TKA decisions. Thiswouldhelpdeter- asymmetrywasinvestigated,whereasymmetryofothermus-\nminewhetherfunctionallimitationsreportedbypatientsalign cle groups (i.e., hamstrings and calves) may also influence\nwithordivergefromstrengthdeficits,furtherrefiningriskas- TKArisk.Additionally,musclestrengthandsymmetrystatus\nsessmentandinterventionstrategies. were only investigated at baseline, preventing longitudinal\nThisworkhighlightsthatkneeextensorstrengthasymme- analysisofmusclestrengthandsymmetrychangesovertime.\ntry is associated with risk of TKA independently of absolute Limbdominancewasalsonotaccountedfor,whichmayinflu-\nweakness. Although lower overall strength is associated with ence strength asymmetry independent of pathology. Further-\nknee OA progression,7 this study found that absolute weak- more,arthrogenicmuscularinhibition,aneuralinhibitionpro-\nness, defined relative to peers with similar demographic and cesswherejointdamageorinflammationdisruptsnormalmuscle\nclinicalcharacteristics,didnotsignificantlypredictTKArisk activation,mayhavecontributedtostrengthasymmetryrather\noncestrengthasymmetrywastakenintoaccount.Notably,in- thanasymmetryleadingtodiseaseprogression.arthrogenic\ndividualswithgreater rightversusleftkneeextensorstrength muscularinhibitionresultsinreflexiveinhibitionatthespinal\nwereatanincreasedriskofleftTKAcomparedtothosewith cordlevel, potentially reducingvoluntary musclerecruitment\nsymmetricalstrength.Thesefindingsemphasizethat,inaddi- onthemoreaffectedside,whichcomplicatestheabilitytoin-\ntiontomeasuringstrengthsymmetry,cliniciansshouldidentify fercausality.Additionally,whilethefindingssuggestastrong\nwhich limb is weaker, and potentially at greatest risk. Estab- associationbetweenstrengthasymmetryandTKArisk,causal-\nlishinguniversalabsolutestrengthcutoffsremainschallenging ity cannot be definitively established. Future research should\nbecause of variability in body size, sex, and other individual aim to address these limitations by exploring the effects of\nfactors.Incontrast,identifyingastrengthasymmetryexceeding comprehensive,multifactorialinterventionsonkneeOAout-\n10%appearstoofferamorepracticalandclinicallymeaningful comes. Despite these limitations, the study is the first to in-\n“red flag” for detecting individuals at increased TKA risk, re- vestigatemusclestrengthasymmetryasapredictorofTKA,\ngardlessoftheirabsolutestrengthlevels.Futurestudiesshould providing critical insights into the importance of addressing\nexplore whether a minimal strength threshold, in addition to strengthimbalancesinclinicalsettings.\nthe10%asymmetry,contributestorisk.Regardless,developing\nknee OA-specific symmetry training programs could help re-\nCONCLUSIONS\nduce the risk of TKA in individuals with or at risk for knee\nInconclusion,kneeextensorstrengthasymmetrywasas-\nOA.Strengthtraininghasbeenshowntobebothsafeandeffec-\nsociated with 10-yr TKA risk, a greater than 10% reduction\ntiveforincreasingforceproductioninolderadults,withrecom-\nmendationsof3–4sessionsperweekforoptimalresults.29 inrightkneeextensorstrengthisassociatedwithincreasedrisk\nofrightTKAandagreaterthan10%reductioninleftkneeex-\nThemajorityofactivitiesofdailyliving,suchaswalking,\ntensor strength is associated with increased risk of left TKA.\nstairambulation,andrisingfromachair,aregenerallyconsid-\nThesefindingsunderscoretheneedfortargetedkneeextensor\neredsymmetricalmovements;however,theyrequireadelicate\nstrengthening programs aimed at achieving and maintaining\nbalance of force generation between both limbs to perform\nthesetaskseffectively.30Agreaterthan10%differenceinknee strengthsymmetry, potentially reducing TKA riskinindivid-\nualswithoratriskofkneeOA.\nextensorstrengthbetweenkneesmaydisruptthisbalance,par-\nticularlyduringmoredemandingfunctionaltasks.Previousre-\nsearchhasshownthatindividualswithkneeOAoftencompen- ACKNOWLEDGMENTS\nsatebyrelyingmoreheavilyontheircontralateralkneewhen TheauthorsthanktheOsteoarthritisInitiative(OAI)par-\ntheiraffectedkneehasreducedextensorstrength.30Agreater ticipants,andthestudyinvestigatorsandcoordinatorsateach\n1138\nwww.ajpmr.com ©2025WoltersKluwerHealth,Inc.Allrightsreserved.\n\n--- PAGE 7 ---\nVolume104,Number12,December2025 StrengthAsymmetryandTKA:ASurvivalAnalysis\nofthefoursites.TheOAIisadatarepositoryhousedwithinthe 13. ArhosEK,ThomaLM,GrindemH,etal:Associationofquadricepsstrengthsymmetryand\nNIMHDataArchive(NDA).TheOAIisacollaborativeinfor- surgicalstatuswithclinicalosteoarthritisfiveyearsafteranteriorcruciateligamentrupture.\nArthritisCareRes2022;74:386–91\nmatics system created by the National Institute of Mental\n14. NevittM,FelsonD,LesterG:Protocolforthecohortstudy.1.Publishedonline2006.\nHealthandtheNationalInstituteofArthritis,Musculoskeletal Availableat:https://oai.epi-ucsf.org/datarelease/About.asp.AccessedApril14,2024\nandSkinDiseases(NIAMS)toprovideaworldwideresourceto 15. KellgrenJH,LawrenceJS:Radiologicalassessmentofosteo-arthrosis.AnnRheumDis1957;\n16:494–502\nquickenthepaceofbiomarkeridentification,scientificinvesti-\n16. RantanenT,EraP,HeikkinenE:Physicalactivityandthechangesinmaximalisometric\ngationandOAdrugdevelopment.OAIdataareavailableina strengthinmenandwomenfromtheageof75to80years.JAmGeriatrSoc1997;45:1439–45\npublic,openaccessrepository(https://nda.nih.gov/oai) 17. VaattovaaraE,PanfilovE,TiulpinA,etal:Kellgren-Lawrencegradingofkneeosteoarthritis\nusingdeeplearning:diagnosticperformancewithexternaldatasetandcomparisonwithfour\nreaders.OsteoarthrCartilOpen2025;7:100580\n18. SalaffiF,StancatiA,AlbertoSilvestriC,etal:Minimalclinicallyimportantchangesin\nREFERENCES\nchronicmusculoskeletalpainintensitymeasuredonanumericalratingscale.EurJPain2004;\n1. AllenKD,ThomaLM,GolightlyYM:Epidemiologyofosteoarthritis.OsteoarthrCartil 8:283–91\n2022;30:184–95 19. RobinsonRO,HerzogW,NiggBM:Useofforceplatformvariablestoquantifytheeffectsof\n2. LongH,LiuQ,YinH,etal:Prevalencetrendsofsite-specificosteoarthritisfrom1990to2019: chiropracticmanipulationongaitsymmetry.JManipulativePhysiolTher1987;10:172–6\nfindingsfromtheGlobalBurdenofDiseaseStudy2019.ArthritisRheumatol2022;74:1172–83 20. PattersonBE,CrossleyKM,PerratonLG,etal:Limbsymmetryindexonafunctionaltest\n3. SteinhausME,ChristAB,CrossMB:Totalkneearthroplastyforkneeosteoarthritis:support batteryimprovesbetweenoneandfiveyearsafteranteriorcruciateligamentreconstruction,\nforaforegoneconclusion?HSSJ2017;13:207–10 primarilyduetoworseningcontralaterallimbfunction.PhysTherSport2020;44:67–74\n4. MarshJ,JoshiI,SomervilleL,etal:Healthcarecostsaftertotalkneearthroplastyforsatisfied 21. DudleyWN,WickhamR,CoombsN:Anintroductiontosurvivalstatistics:kaplan-meier\nanddissatisfiedpatients.CanJSurg2022;65:E562–6 analysis.JAdvPractOncol2016;7:91–100\n5. CanadianInstituteforHealthInformation:WaitTimesforPriorityProceduresinCanada.May 22. HatfieldGL,CostelloKE,AstephenWilsonJL,etal:Baselinegaitmuscleactivationpatterns\n10,2022.Availableat:https://www.cihi.ca/en/wait-times-for-priority-procedures-in-canada- differforosteoarthritispatientswhoundergototalkneearthroplastyfivetoeightyearslater\n2022.AccessedMay26,2024 fromthosewhodonot.ArthritisCareRes2021;73:549–58\n6. JohnsonVL,HunterDJ:Theepidemiologyofosteoarthritis.BestPractResClinRheumatol 23. PanjabiMM:Thestabilizingsystemofthespine.PartI.Function,dysfunction,adaptation,\n2014;28:5–15 andenhancement.JSpinalDisord1992;5:383–9\n7. ØiestadBE,JuhlCB,CulvenorAG,etal:Kneeextensormuscleweaknessisariskfactorfor 24. MillsK,HuntMA,LeighR,etal:Asystematicreviewandmeta-analysisoflowerlimb\nthedevelopmentofkneeosteoarthritis:anupdatedsystematicreviewandmeta-analysis neuromuscularalterationsassociatedwithkneeosteoarthritisduringlevelwalking.Clin\nincluding46819menandwomen.BrJSportsMed2022;56:349–55 Biomech2013;28:713–24\n8. CulvenorAG,RuhdorferA,JuhlC,etal:Kneeextensorstrengthandriskofstructural, 25. RutherfordD,BakerM,WongI,etal:Theeffectofageandkneeosteoarthritisonmuscle\nsymptomatic,andfunctionaldeclineinkneeosteoarthritis:asystematicreviewandmeta- activationpatternsandkneejointbiomechanicsduringdualbelttreadmillgait.JElectromyogr\nanalysis.ArthritisCareRes2017;69:649–58 Kinesiol2017;34:58–64\n9. KrishnasamyP,HallM,RobbinsSR:Theroleofskeletalmuscleinthepathophysiologyand 26. ArdenNK,PerryTA,BannuruRR,etal:Non-surgicalmanagementofkneeosteoarthritis:\nmanagementofkneeosteoarthritis.Rheumatology2018;57(suppl_4):iv22–33 comparisonofESCEOandOARSI2019guidelines.NatRevRheumatol2021;17:59–66\n10. Palmieri-SmithRM,ThomasAC,Karvonen-GutierrezC,etal:Isometricquadricepsstrength 27. FelsonD,NeogiT:Aclinician’sperspectiveontheroleofimaginginkneeosteoarthritisin\ninwomenwithmild,moderate,andseverekneeosteoarthritis.AmJPhysMedRehabil2010; clinicalpractice.SkeletalRadiol2023;52:2007–10\n89:541–8 28. RoosEM,LohmanderLS:TheKneeinjuryandOsteoarthritisOutcomeScore(KOOS):from\n11. BennellKL,WrigleyTV,HuntMA,etal:Updateontheroleofmuscleinthegenesisand jointinjurytoosteoarthritis.HealthQualLifeOutcomes2003;1:64\nmanagementofkneeosteoarthritis.RheumDisClin2013;39:145–76 29. MayerF,Scharhag-RosenbergerF,CarlsohnA,etal:Theintensityandeffectsofstrength\n12. BrunstC,IthurburnMP,ZbojniewiczAM,etal:Return-to-sportquadricepsstrength trainingintheelderly.DtschÄrzteblInt2011;108:359–64PublishedonlineMay27,2011\nsymmetryimpacts5-yearcartilageintegrityafteranteriorcruciateligamentreconstruction:a 30. VanRossomS,EmmerzaalJ,vanderStraatenR,etal:Thebiomechanicalfingerprintofhip\npreliminaryanalysis.JOrthopRes2022;40:285–94 andkneeosteoarthritispatientsduringactivitiesofdailyliving.ClinBiomech.2023;101:105858\n1139\n©2025WoltersKluwerHealth,Inc.Allrightsreserved. www.ajpmr.com\n",
  "Article 2: keaf686": "\n--- PAGE 1 ---\nPage 1 of 107 Rheumatology\nRheumatology RHE-25-2165.R1\n1\n2\n3\n4\nAn interpretable metabolomic-driven machine learning model for early\n5 prediction of knee structural osteoarthritis progression\n6\n7 Afshin Jamshidi1, Guangju Zhai2, Ming Liu2, Weidong Zhang3, Graeme Jones4,\n8\nFlavia M. Cicuttini5, Jean-Pierre Pelletier1, Johanne Martel-Pelletier1\n9\n10\n11\n12\n13\n1 Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM),\n14\nMontreal, Quebec, Canada.\n15\n16 2 Human Genetics & Genomics, Division of Biomedical Sciences, Faculty of Medicine,\n17 Memorial University of Newfoundland, St. John’s, Newfoundland, Canada.\n18 3 School of Pharmaceutical Sciences, Jilin University, Changchun, P.R., China.\n19 4 Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.\n20\n5 School of Public Health and Preventive Medicine, Monash University, and Department of\n21\nRheumatology, Alfred Hospital, Melbourne, Victoria, Australia.\n22\n23\n24\n25 Correspondence to: Johanne Martel-Pelletier, PhD, Osteoarthritis Research Unit, University of\n26\n27 Montreal Hospital Research Centre (CRCHUM), 900 Saint-Denis, R11.412B, Montreal, Quebec\n28\nH2X 0A9 Canada. Tel.: 514-890-8000 ext. 27281; Fax: 514-412-7582; E-mail:\n29\n30\njm@martelpelletier.ca\n31\n32\n33\n34\n35 ORCID\n36\n37 Afshin Jamshidi, PhD: https://orcid.org/0009-0003-0190-2364\n38\nGuangju Zhai, PhD: https://orcid.org/0009-0005-0088-6838\n39\n40 Ming Liu, MSc: https://orcid.org/0000-0001-7745-448X\n41\nWeidong Zhang, PhD: https://orcid.org/0000-0002-0843-5688\n42\n43\nGraeme Jones, MD, PhD: http://orcid.or/0000-0001-9109-7255\n44\n45 Flavia M. Cicuttini, PhD: https://orcid.org/0000-0002-8200-1618\n46\nJean-Pierre Pelletier, MD: https://orcid.org/0000-0001-9930-6453\n47\n48\nJohanne Martel-Pelletier, PhD: https://orcid.org/0000-0003-2618-383X\n49\n50\n51\n52\n53\n54\n55\n56\n57\n58\n59 © The Author(s) 2025. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights 1\n60\nreserved. For permissions, please email: journals.permissions@oup.com\nDownloaded\nfrom\nhttps://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keaf686/8402357\nby\nUniversiteitsbibliotheek\nUtrecht\nuser\non\n24\nDecember\n2025\n\n--- PAGE 2 ---\nRheumatology Page 2 of 107\nRheumatology RHE-25-2165.R1\n1\n2\n3 Abstract\n4\n5\n6 Objectives. Osteoarthritis (OA) is the most prevalent chronic musculoskeletal disease. Early\n7\nidentification of individuals at risk of knee structural progression is essential for targeted\n8\n9\ninterventions. This study aimed to develop and validate a machine/deep learning (ML/DL)-based\n10\n11 prognostic model for knee OA progression using serum metabolomics.\n12\n13\nMethods. Baseline serum metabolomic factors from two independent cohorts were analyzed:\n14\n15 Tasmanian Older Adult Cohort (n=180) for model development and Licofelone trial (n=137) for\n16\n17 external validation. Participants were categorized by likelihood of knee structural progression\n18\nusing MRI and X-ray data. Four metabolomic scenarios were evaluated: metabolites alone (104),\n19\n20\nplus their ratios or inverse ratios (each 5,460), and all combined (10,816), alongside age, sex, BMI.\n21\n22 Metabolomic profiling used high-throughput omics. Batch effects were corrected via ComBat.\n23\n24 Feature selection combined variable clustering with elastic net regularization. Top-selected\n25\nfeatures of each scenario were trained using five ML/DL models, with performance assessed by\n26\n27\nAUC, accuracy, sensitivity, and specificity with 95% confidence intervals.\n28\n29\nResults. The metabolomic-only scenario, including sex and age, yielded the best performance.\n30\n31\nFeature clustering reduced to 22, with the top 10 used for training/testing. The Artificial Neural\n32\n33 Network with domain-adversarial component outperformed other algorithms with domain shift.\n34\n35 The final model, including six metabolites (SM (OH) C22:2, proline, citrulline, LysoPC a C18:0,\n36\nglutamate, and C12-DC), plus sex and age, demonstrated excellent predictive performance (test:\n37\n38\nAUC 0.98[0.95,1], accuracy 0.89[0.84,0.94]; validation: AUC 0.89[0.83,0.95], accuracy\n39\n40 0.85[0.79,0.91]).\n41\n42\nConclusion. This validated metabolomics DL framework\n43\n44 (https://github.com/AFSHINJAM/KOA_Prediction_Metabolomics_Ratios) introduces a novel\n45\n46 approach for predicting knee OA structural progression, enabling personalized risk assessment and\n47\nearly intervention.\n48\n49\n50 Short title: Prognostic prediction of knee osteoarthritis structural progression using metabolomic-\n51\nbased machine learning.\n52\n53\n54 Keywords: Machine/deep learning; prognostic; metabolomics; knee osteoarthritis; biomarkers,\n55\n56 risk factors.\n57\n58\n59 2\n60\nDownloaded\nfrom\nhttps://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keaf686/8402357\nby\nUniversiteitsbibliotheek\nUtrecht\nuser\non\n24\nDecember\n2025\n\n--- PAGE 3 ---\nPage 3 of 107 Rheumatology\nRheumatology RHE-25-2165.R1\n1\n2\n3 Key messages\n4\n5 • Our study introduces a metabolomics-based deep learning model predicting structural\n6 progression in knee osteoarthritis.\n7 • The deep learning model was externally validated, underscoring its generalizability and\n8\nstrengthening its scientific robustness.\n9\n10 • Our findings reveal novel metabolites associated with structural progression in knee\n11 osteoarthritis.\n12\n13\n14\n15\n16\n17\n18\n19\n20\n21\n22\n23\n24\n25\n26\n27\n28\n29\n30\n31\n32\n33\n34\n35\n36\n37\n38\n39\n40\n41\n42\n43\n44\n45\n46\n47\n48\n49\n50\n51\n52\n53\n54\n55\n56\n57\n58\n59 3\n60\nDownloaded\nfrom\nhttps://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keaf686/8402357\nby\nUniversiteitsbibliotheek\nUtrecht\nuser\non\n24\nDecember\n2025\n\n--- PAGE 4 ---\nRheumatology Page 4 of 107\nRheumatology RHE-25-2165.R1\n1\n2\n3 Introduction\n4\n5\n6 Osteoarthritis (OA) is a chronic degenerative joint disorder and a leading global cause of disability,\n7\n8 exerting a growing economic burden on healthcare systems [1, 2]. It manifests as joint pain,\n9\n10\nstiffness, and functional deterioration, harming the quality of life. The knee is often impacted; a\n11\n12\n13 consequence of its critical role in mobility and the considerable mechanical load it bears. OA can\n14\n15 also lead to emotional strain and social difficulties, amplifying its impact [3, 4].\n16\n17\nAlthough typically a slow-progressing condition, some OA patients experience rapid structural\n18\n19\ndeterioration that leads to severe disease in a relatively short time [5, 6]. Diagnosis usually occurs\n20\n21\n22 after substantial joint damage, limiting opportunities for timely intervention and complicating the\n23\n24\ndevelopment of targeted treatment strategies. Current prognostic tools rely heavily on expert\n25\n26\nclinical judgment, introducing subjectivity. These evaluations may be enhanced by imaging\n27\n28\n29 techniques like radiography (X-ray) and magnetic resonance imaging (MRI). Although both\n30\n31 provide structural insights, with MRI being particularly sensitive to early tissue changes, they are\n32\n33\noften limited by the need for expert interpretation.\n34\n35\n36 To improve early risk identification, researchers are turning to machine (ML)/deep (DL) learning\n37\n38 approaches combined with circulating biochemical markers to generate data-driven prognostic\n39\n40\ntools. While much of the previous research has concentrated on genomic or proteomic biomarkers,\n41\n42\nmetabolomics offers a dynamic and integrative view of both physiological and pathophysiological\n43\n44\n45 states, making it particularly well-suited for monitoring disease progression.\n46\n47\nMetabolites are small molecules and represent the end products of cellular metabolism, providing\n48\n49\na real-time snapshot of biochemical activity. As downstream indicators of gene and protein\n50\n51\n52 interactions, metabolites respond dynamically to pathological changes, making them valuable for\n53\n54 disease prediction and prognosis. Although interest in looking for metabolomics in OA has grown\n55\n56\n57\n58\n59 4\n60\nDownloaded\nfrom\nhttps://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keaf686/8402357\nby\nUniversiteitsbibliotheek\nUtrecht\nuser\non\n24\nDecember\n2025\n\n--- PAGE 5 ---\nPage 5 of 107 Rheumatology\nRheumatology RHE-25-2165.R1\n1\n2\n3 in recent years [7-13], the potential of a defined metabolomic signature for predicting structural\n4\n5\nprogression remains insufficiently explored. Developing metabolite-based markers alongside risk\n6\n7\n8 factors for early detection of knee OA structural progression can markedly improve patient\n9\n10 stratification and support earlier, targeted interventions.\n11\n12\nWe hypothesized that ML/DL models trained on unbiased serum metabolomic data could\n13\n14\naccurately predict individuals at high risk of knee OA structural progression. We aimed to develop\n15\n16\n17 a robust, reproducible, and validated automated predictive framework that combines high-\n18\n19\nthroughput metabolomic profiling with advanced ML/DL methodologies. Our ultimate goal is to\n20\n21\nfacilitate personalized OA management and promote precision medicine in OA care.\n22\n23\n24\n25\n26\nMethods\n27\n28\n29\nThis study conforms to the TRIPOD reporting guidelines for prognostic model development [14].\n30\n31\nSample and Cohort Population\n32\n33\n34 Baseline fasting serum samples were collected and stored at -80ºC. Participants were drawn from\n35\n36\ntwo independent cohorts: the Tasmanian Older Adult Cohort (TASOAC) [15, 16] and the\n37\n38\nLicofelone clinical trial [17]. For both cohorts, analyses were conducted using the participant’s\n39\n40\n41 target knee.\n42\n43 The modelling cohort comprised participants from TASOAC, aged 50-80, recruited from the\n44\n45\nelectoral roll in southern Tasmania, Australia [15]. A total of 180 participants with available\n46\n47\n48 metabolomics data [18] were included. Ethical approval was obtained from the Southern\n49\n50 Tasmanian Health and Medical Human Research Ethics Committee.\n51\n52\nFor the external validation, samples were from a Phase III clinical randomized, double-blind trial\n53\n54\ncomparing Licofelone, a lipoxygenase and cyclo-oxygenase inhibitor, to Naproxen in symptomatic\n55\n56\n57\n58\n59 5\n60\nDownloaded\nfrom\nhttps://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keaf686/8402357\nby\nUniversiteitsbibliotheek\nUtrecht\nuser\non\n24\nDecember\n2025\n\n--- PAGE 6 ---\nRheumatology Page 6 of 107\nRheumatology RHE-25-2165.R1\n1\n2\n3 knee OA patients recruited from rheumatology clinics across Canada [17]. A total of 137 patients\n4\n5\nwith available metabolomics data were included [10, 19]. Ethics approval was granted by a central\n6\n7\n8 review board (IRB Institutional Review Board Services, ON, Canada) and the institutional review\n9\n10 board of the Centre hospitalier de l’Université de Sherbrooke (QC, Canada).\n11\n12\nAll patients provided written informed consent, including permission for serum collection and\n13\n14\nbiomarker analysis.\n15\n16\n17 Feature Selection and Predictive Model Development (Figure 1)\n18\n19\nClassification of OA Structural Progressors and Non‑progressors\n20\n21\n22 The outcome was defined as identifying individuals at high risk of structural progression of knee\n23\n24\nOA. Participants were classified as structural progressors or non-progressors using a previously\n25\n26\ndescribed ML algorithm applied to MRI and radiographic data [20-22]. Details are provided in the\n27\n28\n29 Supplementary Methods in Supplementary Data S2.\n30\n31\nMetabolomic Profiling\n32\n33\nTASOAC samples were profiled using two platforms: 59 with Biocrates AbsoluteIDQ® p180 kit\n34\n35\n36 (Biocrates Life Sciences AG, Innsbruck, Austria) and 121 with the Metabolomics Innovation\n37\n38\nCentre (TMIC) Prime Metabolomics Profiling Assay (https://www.metabolomicscentre.ca).\n39\n40\nLicofelone validation cohort samples were analyzed exclusively using the Biocrates\n41\n42\n43 AbsoluteIDQ® p180 kit. A total of 104 metabolites were used, including glycerophospholipids,\n44\n45 acylcarnitines, amino acids, biogenic amines, and sphingolipids. Details for the profiling protocols\n46\n47\nare in the Supplementary Methods in Supplementary Data S2.\n48\n49\n50 Sample Size Estimation\n51\n52 Using the MetSizeR package [23], we estimated the sample size needed to control the false\n53\n54\ndiscovery rate at 0.05, assuming 20% of 104 metabolomic features would show significant\n55\n56\n57\n58\n59 6\n60\nDownloaded\nfrom\nhttps://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keaf686/8402357\nby\nUniversiteitsbibliotheek\nUtrecht\nuser\non\n24\nDecember\n2025\n\n--- PAGE 7 ---\nPage 7 of 107 Rheumatology\nRheumatology RHE-25-2165.R1\n1\n2\n3 differences. For the metabolites plus ratios sets, feature clustering was applied to reduce\n4\n5\ndimensionality in scenarios 2-4 (see Feature Selection Scenarios below). The analysis indicated\n6\n7\n8 that 40 samples are sufficient, confirming our current sample size is adequate.\n9\n10\nData Preprocessing and Outlier Detection\n11\n12\nMetabolomic features were log -transformed and standardized. Sparse Principal Component\n13 2\n14\n15 Analysis (sPCA) was used to detect potential outliers, identified as samples exceeding three\n16\n17 standard deviations from the mean.\n18\n19\nBatch Effect Correction\n20\n21\n22 To address batch effects from different profiling platforms in TASOAC, we applied the\n23\n24 nonparametric ComBat method, evaluated using Shapiro-Wilk tests and sPCA. A null model\n25\n26\nexcluding covariates minimized the risk of confounding effects. The cleaned dataset was used for\n27\n28\n29 all subsequent analyses.\n30\n31\nFeature Selection Scenarios\n32\n33\nWe evaluated four feature sets in which the risk factors, age, sex, and body mass index (BMI),\n34\n35\n36 were included in every scenario: 1) metabolites alone (104); 2) metabolites plus ratios (5,460); 3)\n37\n38 metabolites plus inverse ratios (5,460); 4) metabolites plus both ratios (10,816). Ratios were\n39\n40\nanalyzed as proxies for enzymatic activity.\n41\n42\n43 Dimensionality Reduction and Feature Selection\n44\n45\nFeature Clustering. Highly correlated features were grouped using the VarClusHi algorithm\n46\n47\n(https://github.com/jingtt/varclushi; Python implementation). Before clustering, in scenarios 2-4,\n48\n49\n50 low variance features were filtered utilizing dynamic thresholds to reduce noise and computational\n51\n52 load\n53\n54\n55\n56\n57\n58\n59 7\n60\nDownloaded\nfrom\nhttps://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keaf686/8402357\nby\nUniversiteitsbibliotheek\nUtrecht\nuser\non\n24\nDecember\n2025\n\n--- PAGE 8 ---\nRheumatology Page 8 of 107\nRheumatology RHE-25-2165.R1\n1\n2\n3 (https://scikitlearn.org/stable/modules/generated/sklearn.feature_selection.VarianceThreshold.ht\n4\n5\nml).\n6\n7\n8 Predictive Feature Selection. Regularized logistic regression with an elastic net penalty was further\n9\n10 applied to select the top 10 most predictive features (metabolites plus risk factors) per scenario.\n11\n12\nFeatures were standardized to prevent scale bias. Absolute regression coefficients ranked feature\n13\n14\nimportance.\n15\n16\n17 Machine/Deep Learning Model Development\n18\n19\nTraining and Class Imbalance Correction. The dataset was randomly divided into 80% training\n20\n21\n22 and 20% testing, with classification labels determined as described above. To address class\n23\n24 imbalances in the training data, we applied the Synthetic Minority Over-sampling Technique\n25\n26\n(SMOTE) in each scenario. In our dataset, class imbalance refers to the unequal distribution of\n27\n28\nprogressors and non-progressors, with progressors representing 32% (n=57) in TASOAC and 72%\n29\n30\n31 (n=99) in Licofelone. SMOTE generated synthetic progressors to improve model balance.\n32\n33\nPerformance was evaluated using the area under the curve (AUC), accuracy (ACC), sensitivity,\n34\n35\nand specificity with their 95% confidence interval (CI) for the optimal model (AUC [24]; other\n36\n37\n38 metrics [25]).\n39\n40 Model Selection. For the development of the prediction model, we selected the top 10 features\n41\n42\n(metabolites plus risk factors where appropriate) for each scenario. We tested four ML\n43\n44\n45 (Regularized Logistic Regression, Support Vector Machines (SVM), Random Forest, and Extreme\n46\n47 Gradient Boosting (XGBoost)) models and one DL, Artificial Neural Networks (ANN) model per\n48\n49\nscenario.\n50\n51\nDomain Adaptation. To improve generalizability across cohorts, domain adaptation strategies\n52\n53\n54 were implemented. ML models used sample reweighting based on density ratio estimation (DW).\n55\n56\n57\n58\n59 8\n60\nDownloaded\nfrom\nhttps://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keaf686/8402357\nby\nUniversiteitsbibliotheek\nUtrecht\nuser\non\n24\nDecember\n2025\n\n--- PAGE 9 ---\nPage 9 of 107 Rheumatology\nRheumatology RHE-25-2165.R1\n1\n2\n3 For the DL model, a Domain-Adversarial Neural Network (DANN) was implemented in\n4\n5\nTensorFlow using the top-ranked 10 features. Implementation details are in the Supplementary\n6\n7\n8 Methods in Supplementary Data S2. For the optimal model, we conducted an iterative feature\n9\n10 selection process, evaluating each model using various feature subsets, ranging from five to ten.\n11\n12\nFeature Interpretation\n13\n14\n15 To interpret model predictions, we employed SHapley Additive exPlanations (SHAP), which\n16\n17 provide a consistent framework for interpreting model predictions by quantifying each feature’s\n18\n19\ncontribution to the prediction. Features were ranked on their absolute SHAP values. SHAP\n20\n21\n22 estimates the marginal impact of each feature on the output by evaluating all possible\n23\n24 combinations, thereby providing a thorough measure of feature importance. In addition, SHAP\n25\n26\nvalues indicate the directionality (positive or negative) of each feature's effect on the\n27\n28\nprediction. Further, we generated Partial dependence plots (PDPS), which illustrated how\n29\n30\n31 individual features influence prediction probabilities, offering insights into model behaviour.\n32\n33\n34\n35\nResults\n36\n37\n38\nBaseline Characteristics of Participants\n39\n40\nTable 1 presents baseline characteristics for modelling (TASOAC) and validation (Licofelone)\n41\n42\n43 cohorts. Although the mean age was similar, other characteristics showed statistical differences.\n44\n45 The validation cohort had fewer males (p=0.008), higher BMI (p≤0.001), and more severe OA,\n46\n47\nreflected by higher Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)\n48\n49\n50 scores (all p≤0.001), greater joint space narrowing (JSN) (p≤0.001), and reduced joint space width\n51\n52 (JSW) (p≤0.001).\n53\n54\n55\n56\n57\n58\n59 9\n60\nDownloaded\nfrom\nhttps://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keaf686/8402357\nby\nUniversiteitsbibliotheek\nUtrecht\nuser\non\n24\nDecember\n2025\n\n--- PAGE 10 ---\nRheumatology Page 10 of 107\nRheumatology RHE-25-2165.R1\n1\n2\n3 TASOAC Outlier Detection and Batch Correction\n4\n5\nsPCA identified no clear outliers. One sample exhibited a z-score near the threshold of 3; however,\n6\n7\n8 it was retained due to its marginal deviation and limited sample size of the TASOAC cohort\n9\n10 (Supplementary Figure S1A). ComBat correction substantially improved sample distribution\n11\n12\nacross batches, resulting in a more uniform sample distribution and minimizing clustering\n13\n14\nattributable to methodological differences (Supplementary Figure S1B).\n15\n16\n17 Feature Clustering\n18\n19\nVariance thresholding applied to scenarios 2-4 reduced the metabolites as follows: metabolites\n20\n21\nplus ratios from 5,460 to 898, metabolites plus reversed ratios from 5,460 to 1,121, all combined\n22\n23\n24 from 10,816 to 946.\n25\n26 Applying VarClusHi clustering narrowed the metabolites to 22, 121, 131, and 124 across scenarios\n27\n28\n1-4, respectively (Supplementary Table S1 with the chosen clustering features highlighted in bold).\n29\n30\n31 Feature Selection\n32\n33\nFigure 2 represents the top 10 features (metabolites plus risk factors where appropriate) per\n34\n35\nscenario, selected based on the absolute regression coefficients. Of note, in the metabolites-only\n36\n37\n38 model, Sex_1 (females) was retained over Sex_0 (males), likely indicating stronger predictive\n39\n40 power. However, males were subjected to further analysis.\n41\n42\nPrediction Model Development\n43\n44\n45 Figure 3 shows that ML/DL models tested on the top 10 features (comprising metabolites plus\n46\n47 relevant risk factors) performed suboptimally across different scenarios, with weaker results in the\n48\n49\nvalidation cohort. Notably, both females and males were included in the model analysis.\n50\n51\n52 To improve model performance, we applied sample reweighting and domain adaptation based on\n53\n54 the top 10 predictive features (Figure 4). For the ML models, although this improved distribution,\n55\n56\n57\n58\n59 10\n60\nDownloaded\nfrom\nhttps://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keaf686/8402357\nby\nUniversiteitsbibliotheek\nUtrecht\nuser\non\n24\nDecember\n2025\n\n--- PAGE 11 ---\nPage 11 of 107 Rheumatology\nRheumatology RHE-25-2165.R1\n1\n2\n3 it did not fully resolve domain shift, as the AUC and accuracy remained below 0.80. In contrast,\n4\n5\nthe ANN-DANN model yielded a significant improvement, consistently outperforming the other\n6\n7\n8 ML models on both test and validation datasets. This was particularly evident in scenario 1\n9\n10 (metabolites only plus sex and age), where performance metrics reached outstanding to excellent\n11\n12\nlevels on both the test and validation sets (Figure 4).\n13\n14\n15 Optimal Prediction Model\n16\n17 To establish the most effective prediction model, we systematically varied the composition of\n18\n19\nfeature subsets, ranging from five to ten features. Data indicated that scenario 1 achieved similar\n20\n21\n22 results with 8 features (6 metabolites plus sex and age) using the ANN-DANN model. In contrast,\n23\n24 the other scenarios (2-4) achieved optimal performance with the 10 features (9 metabolites plus\n25\n26\nBMI).\n27\n28\nThe ANN-DANN model of scenario 1 included 6 metabolites: hydroxysphingomyelin (SM (OH))\n29\n30\n31 C22:2, proline, citrulline, lysophosphatidylcholine (LysoPC) a C18:0, glutamate, and\n32\n33\ndodecanedioylcarnitine (C12-DC), along with sex and age. Test set performance was: AUC 0.98\n34\n35\n[0.95,1], ACC 0.89 [0.84,0.94], sensitivity 0.83 [0.72,0.94], specificity 0.91 [0.85,0.97], which\n36\n37\n38 was maintained in the external validation cohort, with 0.89 [0.83,0.95], 0.85 [0.79,0.91], 0.87\n39\n40 [0.77,0.97], and 0.81 [0.73,0.89], respectively.\n41\n42\nOptimal Model Features Contribution to the Predictive Model and their Importance to OA\n43\n44\n45 Structural Progression\n46\n47 SHAP analysis (Figure 5A) ranked SM (OH) C22:2 as the most influential feature, followed by\n48\n49\nproline, citrulline, sex, age, LysoPC a C18:0, glutamate, and C12-DC. While the ranking reflected\n50\n51\n52 the average magnitude of each feature’s contribution, regardless of direction, we further visualized\n53\n54 the distribution of SHAP values. Figure 5B shows that SM (OH) C22:2 exhibited the broadest\n55\n56\n57\n58\n59 11\n60\nDownloaded\nfrom\nhttps://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keaf686/8402357\nby\nUniversiteitsbibliotheek\nUtrecht\nuser\non\n24\nDecember\n2025\n\n--- PAGE 12 ---\nRheumatology Page 12 of 107\nRheumatology RHE-25-2165.R1\n1\n2\n3 range of values, with higher levels (red dots) predominantly linked with increased OA progression\n4\n5\nrisk; lower levels (blue dots) suggested a potential protective effect or a reduced risk of\n6\n7\n8 progression. Proline and glutamate were consistently associated with progression. Citrulline\n9\n10 showed variability, with higher levels linked to a reduced likelihood of OA progression. Females\n11\n12\n(red dots) had a higher predicted risk than males (blue dots). As expected, age showed a positive\n13\n14\ncorrelation, especially in middle age. LysoPC a C18:0 and C12-DC are also generally associated\n15\n16\n17 with an elevated risk progression.\n18\n19\nWe further examined the PDPs that assess the impact of changes in each feature across its range\n20\n21\nof values. As sex is a categorical feature, we analyzed the model’s behaviour separately for females\n22\n23\n24 and males. Sex-stratified analysis revealed a 6% higher predicted probability of progression in\n25\n26 females (0.38 vs. 0.32), underscoring sex as a binary risk modifier, with females independently\n27\n28\ncontributing to an increased likelihood of progression.\n29\n30\n31 PDPs (Figure 5C) confirmed positive associations for SM (OH) C22:2, proline, and glutamate. In\n32\n33 contrast, citrulline, age, LysoPC a C18:0, and C12-DC displayed nonlinear patterns. Intermediate\n34\n35\nlevels of LysoPC a C18:0 and citrulline had a greater impact than extremes. Age exhibited a peak\n36\n37\neffect at mid-range values. C12-DC generally increased with a decline or plateau at lower\n38\n39\n40 concentrations.\n41\n42\n43\n44\n45 Discussion\n46\n47\nThis study introduced an interpretable DL model capable of predicting knee OA structural\n48\n49\n50 progression using a serum metabolomic signature. Publicly available on GitHub\n51\n52 (https://github.com/AFSHINJAM/KOA_Prediction_Metabolomics_Ratios), the model includes\n53\n54\nsix baseline serum metabolites, SM (OH) C22:2, proline, citrulline, LysoPC a C18:0, glutamate,\n55\n56\n57\n58\n59 12\n60\nDownloaded\nfrom\nhttps://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keaf686/8402357\nby\nUniversiteitsbibliotheek\nUtrecht\nuser\non\n24\nDecember\n2025\n\n--- PAGE 13 ---\nPage 13 of 107 Rheumatology\nRheumatology RHE-25-2165.R1\n1\n2\n3 and C12-DC, alongside sex and age. It achieved excellent performance (AUC 0.98; accuracy 0.89)\n4\n5\non the test set and generalized very well to an external validation cohort (AUC 0.89; ACC 0.85).\n6\n7\n8 Among predictors, SM (OH) C22:2 and glutamate were strongly and positively associated with\n9\n10 OA structural progression, while others demonstrated nonlinear effects, in which intermediate\n11\n12\nvalues influenced predictions differently than extreme concentrations. Females had a slightly\n13\n14\nhigher risk of OA structural progression than males.\n15\n16\n17 Early OA prognosis remains a significant clinical challenge, mainly due to the poor sensitivity of\n18\n19\ncurrent diagnostic methods and the weak symptom-structure correlation [26, 27]. As such,\n20\n21\ninvestigating upstream molecular changes may provide a more precise prognostic approach [28,\n22\n23\n24 29]. While previous studies have explored some “omics” technologies with OA-related tissue,\n25\n26 evaluation of serum metabolomic signature specifically for OA structural progression prediction\n27\n28\nremains underexplored. Metabolomics offers a dynamic readout of biochemical activity, serving\n29\n30\n31 as highly dynamic and sensitive indicators of changes related to diseases [30], more particularly\n32\n33 on joint impairments and cartilage health [31, 32].\n34\n35\nDespite prior studies linking individual metabolites to OA severity [7-13], to our knowledge, none\n36\n37\nhave used a ML/DL approach to predict structural progression with high-dimensional metabolic\n38\n39\n40 datasets (10,816 combining metabolites and ratios). Our approach, leveraging high-throughput\n41\n42\ntechnologies with ML/DL algorithms, enables a fully data-driven selection of relevant predictors,\n43\n44\nidentifying non-intuitive metabolic factors that traditional models might overlook.\n45\n46\n47 A key element of our model’s success was integrating domain adaptation into our ML/DL models\n48\n49 to align latent feature representations between cohorts, addressing dataset distributional shifts\n50\n51\nbetween the modelling (TASOAC), a community-based cohort with generally milder OA, and the\n52\n53\n54 external (Licofelone) cohorts, which consisted of patients with a more advanced disease. TASOAC\n55\n56\n57\n58\n59 13\n60\nDownloaded\nfrom\nhttps://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keaf686/8402357\nby\nUniversiteitsbibliotheek\nUtrecht\nuser\non\n24\nDecember\n2025\n\n--- PAGE 14 ---\nRheumatology Page 14 of 107\nRheumatology RHE-25-2165.R1\n1\n2\n3 had about 44% less progressors than Licofelone, reflecting differences in study design and\n4\n5\nparticipant selection. The OA structural progression definition based on MRI and X-ray data may\n6\n7\n8 have further contributed to such heterogeneity. Despite this, ANN with the domain adaptation\n9\n10 DANN outperformed all other algorithms, which may stem from three main advantages. First,\n11\n12\nANNs can capture complex, nonlinear relationships between features, which are often difficult for\n13\n14\nML models. The metabolomic and demographic features may interact in subtle, non-additive ways,\n15\n16\n17 patterns that ANN can identify more effectively than ML models. Second, domain adaptation\n18\n19\nminimized distributional shift, ensuring consistent feature representation across datasets rather\n20\n21\nthan dataset-specific patterns. Third, unlike ML models that interpret feature importance per\n22\n23\n24 sample, ANNs aggregate and leverage multiple feature dependencies simultaneously, making\n25\n26 them more adaptable across individuals.\n27\n28\nThe interpretability of the predictive model, done using SHAP and PDPs, provides insight into\n29\n30\n31 feature behaviour and offers a dynamic story. SHAP captures feature influence per individual,\n32\n33 while PDPs reveal the average directional impact when varying one feature in isolation.\n34\n35\nSM (OH) C22:2, the top-ranked metabolite, belongs to the sphingolipid family. While its specific\n36\n37\nrole in OA remains partially understood, this metabolite is involved in inflammatory regulation,\n38\n39\n40 cell membrane integrity and apoptosis, which contribute to chondrocyte death and synovial\n41\n42\ninflammation, both central mechanisms in OA progression [33-35]. High concentrations were\n43\n44\nassociated with increased progression risk, suggesting a lipid dysregulation.\n45\n46\n47 Proline was another strong positive predictor. Its role may seem paradoxical, as proline is a key\n48\n49 amino acid involved in collagen biosynthesis, which is essential for the structural integrity of\n50\n51\ncartilage. However, its elevated levels in circulation may indicate collagen breakdown, consistent\n52\n53\n54\n55\n56\n57\n58\n59 14\n60\nDownloaded\nfrom\nhttps://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keaf686/8402357\nby\nUniversiteitsbibliotheek\nUtrecht\nuser\non\n24\nDecember\n2025\n\n--- PAGE 15 ---\nPage 15 of 107 Rheumatology\nRheumatology RHE-25-2165.R1\n1\n2\n3 with cartilage degradation [36, 37]. This catabolic signal may also promote inflammation,\n4\n5\nreinforcing its role in disease progression.\n6\n7\n8 Citrulline showed a nonlinear association (inverted J-shaped with an elongated tail), with lower\n9\n10 levels predicting higher risk and attenuation at higher concentrations. As a non-essential amino\n11\n12\nacid involved in the urea cycle and nitric oxide (NO) metabolism, insufficient citrulline could\n13\n14\nimpair NO-mediated function or antioxidative signalling in cartilage [38], while regulatory\n15\n16\n17 mechanisms may buffer excessive levels.\n18\n19\nLysoPC a C18:0, a lysophospholipid is involved in membrane remodelling and inflammation.\n20\n21\nRegarding OA, studies link LysoPCs, including LysoPC a C18:0, to this disease progression [39]\n22\n23\n24 as well as LysoPC/PC ratios to advanced knee OA and cartilage volume loss over two years [7,\n25\n26 10]. It exhibited an inverted U-shape relationship with OA risk. Moderate elevations may signal\n27\n28\nOA progression risk, while extremes could reflect a reduced risk of progression. Low\n29\n30\n31 concentrations may signify an inadequate repair signalling and higher levels a shift towards anti-\n32\n33 inflammatory or resolution pathways.\n34\n35\nGlutamate, a multifunctional amino acid and traditionally recognized as a neurotransmitter, also\n36\n37\nplays critical roles in nitrogen transport, amino acid biosynthesis, and energy metabolism, all of\n38\n39\n40 which are involved in the OA process. It has been found elevated in the synovial fluid of patients\n41\n42\nwith active arthropathies [40, 41]. In joint tissues, it acts as a signalling molecule, leading to\n43\n44\nenhanced reactive oxygen species (ROS) production, where it can modulate chondrocyte function\n45\n46\n47 and inflammatory cascades [42, 43]. This appears to occur due to an altered modulation of N-\n48\n49 methyl-d-aspartic acid receptors, where, in OA, an additional subunit is expressed [42, 44]. Its\n50\n51\nconsistent positive association with OA progression is also supported by its link to obesity and\n52\n53\n54 metabolic syndrome [45, 46], both OA risk factors. This further reinforces its pro-inflammatory\n55\n56\n57\n58\n59 15\n60\nDownloaded\nfrom\nhttps://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keaf686/8402357\nby\nUniversiteitsbibliotheek\nUtrecht\nuser\non\n24\nDecember\n2025\n\n--- PAGE 16 ---\nRheumatology Page 16 of 107\nRheumatology RHE-25-2165.R1\n1\n2\n3 and metabolically stressed joint environment, which aligns with its association with structural\n4\n5\ndisease progression.\n6\n7\n8 C12-DC, a dicarboxylic acid, is involved in mitochondrial β-oxidation, a key metabolic pathway\n9\n10 for energy production [47]. Its truncated U-shaped PDP suggests a concentration window where\n11\n12\nprogression risk increases. The plateau at low levels suggests metabolic saturation or an adaptive\n13\n14\nbiological response that limits further impact. While its specific role in knee OA remains unclear,\n15\n16\n17 elevated C12-DC may signal impaired mitochondrial fatty acid metabolism, a known contributor\n18\n19\nto oxidative stress and chondrocyte dysfunction [48]. This marker may serve as a proxy for\n20\n21\ndisrupted energy metabolism in joint degradation. Together, these findings support the usefulness\n22\n23\n24 of metabolomics in identifying mechanistic biomarkers of OA structural progression, although\n25\n26 functional validation remains necessary.\n27\n28\nAge and sex also played key roles, reinforcing their well-established demographic risk factors in\n29\n30\n31 OA progression [49, 50]. Age exhibited a reverse-J-shaped PDP, indicating that while risk\n32\n33 increases with age, a plateau or slight decline at advanced ages may reflect reduced sensitivity to\n34\n35\nmetabolic disruptions. Sex differences, with females predicted to have a higher progression risk\n36\n37\nthan males, aligns with established hormonal, biomechanical, and inflammatory differences in OA\n38\n39\n40 susceptibility.\n41\n42\nThe nonlinear effects observed for citrulline, age, LysoPC a C18:0, and C12-DC, highlight the\n43\n44\nlimitations of linear models in capturing biological complexity and support the value of DL\n45\n46\n47 frameworks. Moreover, integrating DANN into ANN was instrumental in maintaining consistent\n48\n49 feature representations across cohorts by dynamically reweighting sample contributions and\n50\n51\ncorrecting for dataset shifts. Another strength of this study lies in the utilization of two distinct\n52\n53\n54 cohorts spanning a spectrum of OA severity. This improves the model’s clinical relevance and\n55\n56\n57\n58\n59 16\n60\nDownloaded\nfrom\nhttps://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keaf686/8402357\nby\nUniversiteitsbibliotheek\nUtrecht\nuser\non\n24\nDecember\n2025\n\n--- PAGE 17 ---\nPage 17 of 107 Rheumatology\nRheumatology RHE-25-2165.R1\n1\n2\n3 ensures representation of both early and advanced structural deterioration, boosting translational\n4\n5\nrobustness. External validation further strengthens confidence in the model’s generalizability.\n6\n7\n8 Importantly, the development of such a predictive model is not intended to replace current clinical\n9\n10 tools but to complement them. It may enhance clinical decision-making by identifying individuals\n11\n12\nat high risk for progression, enabling early intervention through lifestyle, therapy, or\n13\n14\npharmacological approaches. Moreover, it has implications for drug development. The historically\n15\n16\n17 low success rates of disease-modifying OA drug trials, often due to low progression prevalence\n18\n19\n(less than 15%) within standard trial periods [51, 52], could be improved through better participant\n20\n21\nstratification using such models.\n22\n23\n24 As with any study, the present work has limitations. First, both cohorts consisted of Caucasian\n25\n26 participants, limiting generalizability across diverse ethnic populations. Second, the relatively\n27\n28\nsmall sample size and high-dimensional metabolomic dataset raise concerns about overfitting,\n29\n30\n31 although steps were taken to mitigate this. Third, some identified metabolites lack a well-defined\n32\n33 biological role in OA, underscoring the need for functional studies.\n34\n35\nIn conclusion, our findings show that combining serum metabolomics profiles with demographic\n36\n37\nfeatures in interpretable DL models can provide reliable, individualized prediction of knee OA\n38\n39\n40 structural progression. While further validation and translation into clinical practice are required,\n41\n42\nthis approach enhances current understanding in the field and may help identify novel therapeutic\n43\n44\navenues. Importantly, this work also marks a step toward precision OA management that should\n45\n46\n47 facilitate earlier interventions and more effective therapeutic development, which should help alter\n48\n49 the course of this highly prevalent and debilitating disease.\n50\n51\n52\n53\n54\n55\n56\n57\n58\n59 17\n60\nDownloaded\nfrom\nhttps://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keaf686/8402357\nby\nUniversiteitsbibliotheek\nUtrecht\nuser\non\n24\nDecember\n2025\n\n--- PAGE 18 ---\nRheumatology Page 18 of 107\nRheumatology RHE-25-2165.R1\n1\n2\n3 Supplementary Material\n4\n5\n6 The supplementary material provides additional details on the classification of osteoarthritis\n7\n8 structural progressors, the metabolomic profiling, and the machine/deep learning (ML/DL) model\n9\n10\ndevelopment, more specifically on the domain adaptation strategies for both ML and DL models.\n11\n12\n13 Figure S1 demonstrates outlier detection in the TASOAC dataset and the impact of batch\n14\n15 correction. Table S1 outlines the feature thresholding and metabolite clustering for each of the four\n16\n17\nscenarios: 1) metabolites only, 2) metabolites plus ratios, 3) metabolites plus inverse ratios, and 4)\n18\n19\nmetabolites plus all ratios, in addition to the chosen clustering features highlighted in bold.\n20\n21\n22 Acknowledgements\n23\n24\nThe authors wish to thank all the participants from the two cohorts whose contribution made this\n25\n26\n27 study possible, as well as ArthroLab Inc. (Montreal, Quebec, Canada) for providing the magnetic\n28\n29\nresonance imaging data used in this study.\n30\n31\nAuthor Contributions\n32\n33\n34\nAll authors contributed to drafting and/or critically revising the manuscript and approved the final\n35\n36\nversion for publication. Martel-Pelletier and Jamshidi had full access to the study's data and accept\n37\n38\n39 responsibility for the accuracy of the analyses. Zhai and Liu provided metabolic profiling and\n40\n41 ensured data integrity.\n42\n43\nStudy design and conception: Martel-Pelletier, Jamshidi, Pelletier. Data acquisition: Martel-\n44\n45\n46 Pelletier, Zhai, Liu, Zhang, Jones, Cicuttini. Data analysis and interpretation: Martel-Pelletier,\n47\n48 Jamshidi, Pelletier.\n49\n50\n51\n52\n53\n54\n55\n56\n57\n58\n59 18\n60\nDownloaded\nfrom\nhttps://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keaf686/8402357\nby\nUniversiteitsbibliotheek\nUtrecht\nuser\non\n24\nDecember\n2025\n\n--- PAGE 19 ---\nPage 19 of 107 Rheumatology\nRheumatology RHE-25-2165.R1\n1\n2\n3 Financial Support/Role of Funding Source\n4\n5\n6 This work was supported in part by the Osteoarthritis Research Unit of the University of Montreal\n7\n8 Hospital Research Centre and the Chair in Osteoarthritis at the University of Montreal (Montreal,\n9\n10\nCanada).\n11\n12\n13 The funding sources were not involved in the study design, data collection, analysis, interpretation,\n14\n15 manuscript preparation, or the decision to submit for publication.\n16\n17\nAuthor Disclosures/Competing Interests\n18\n19\n20 J-P. Pelletier and J. Martel-Pelletier are shareholders of ArthroLab Inc. All authors declare no\n21\n22\ncompeting interests related to this work.\n23\n24\nEthics\n25\n26\n27\nThe original TASOAC study was funded by the National Health and Medical Research Council\n28\n29\nof Australia (grant number 302204), the Tasmanian Community Fund (grant number D0015018),\n30\n31\n32 the Arthritis Foundation of Australia (grant number MRI06161), and the University of Tasmania\n33\n34\nGrant-Institutional Research Scheme (grant number D0015019). Ethical approval was granted by\n35\n36\nthe Southern Tasmanian Health and Medical Human Research Ethics Committee (reference\n37\n38\n39 number H0006488).\n40\n41 The original Licofelone trial received funding from Merckle GmbH (Ulm, Germany) and\n42\n43\nArthroLab Inc. (Montreal, QC, Canada). It was approved by the Institutional Review Board\n44\n45\n46 Services (Toronto, ON, Canada) and the Institutional Review Board of the Centre hospitalier de\n47\n48 l’Université de Sherbrooke (reference number 9427-A1706-21C).\n49\n50\nMetabolomic profiling for both the TASOAC and Licofelone cohorts was supported by the\n51\n52\nCanadian Institutes of Health Research (CIHR; grant numbers FRN#175015; 153298; 143058;\n53\n54\n55 132178; 191966).\n56\n57\n58\n59 19\n60\nDownloaded\nfrom\nhttps://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keaf686/8402357\nby\nUniversiteitsbibliotheek\nUtrecht\nuser\non\n24\nDecember\n2025\n\n--- PAGE 20 ---\nRheumatology Page 20 of 107\nRheumatology RHE-25-2165.R1\n1\n2\n3 The Institutional Ethics Committee Board of the University of Montreal Hospital Research Centre\n4\n5\n(2018-7290, 17.115 - ID) approved the project.\n6\n7\n8 Informed consent was obtained from all subjects involved in the study.\n9\n10 Data Sharing Statement\n11\n12\n13 The R and Python codes used for feature clustering and selection, and the development of the\n14\n15 Artificial Neural Network (ANN) with Domain Adversarial Neural Network (DANN) prediction\n16\n17\nmodel are available at https://github.com/AFSHINJAM/KOA_Prediction_Metabolomics_Ratios.\n18\n19\nAll other raw data reported in this study are available upon reasonable request to the corresponding\n20\n21\n22 author.\n23\n24\n25\n26\n27\n28\n29\n30\n31\n32\n33\n34\n35\n36\n37\n38\n39\n40\n41\n42\n43\n44\n45\n46\n47\n48\n49\n50\n51\n52\n53\n54\n55\n56\n57\n58\n59 20\n60\nDownloaded\nfrom\nhttps://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keaf686/8402357\nby\nUniversiteitsbibliotheek\nUtrecht\nuser\non\n24\nDecember\n2025\n\n--- PAGE 21 ---\nPage 21 of 107 Rheumatology\nRheumatology RHE-25-2165.R1\n1\n2\n3 References\n4\n5\n6 1 Martel-Pelletier J, Barr AJ, Cicuttini FM, et al. Osteoarthritis. Nat Rev Dis Primers\n7 2016;2:16072.\n8 2 Collaborators GDaI. Global burden of 369 diseases and injuries in 204 countries and\n9\nterritories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.\n10\nLancet 2020;396(10258):1204-22.\n11\n3 Veronese N, Stubbs B, Solmi M, et al. Association between lower limb osteoarthritis and\n12\n13 incidence of depressive symptoms: data from the osteoarthritis initiative. Age Ageing\n14 2017;46(3):470-6.\n15 4 Siviero P, Veronese N, Smith T, et al. Association between osteoarthritis and social isolation:\n16 data from the EPOSA study. J Am Geriatr Soc 2020;68(1):87-95.\n17\n5 Deveza LA, Downie A, Tamez-Pena JG, Eckstein F, Van Spil WE, Hunter DJ. Trajectories\n18\nof femorotibial cartilage thickness among persons with or at risk of knee osteoarthritis:\n19\ndevelopment of a prediction model to identify progressors. Osteoarthritis Cartilage\n20\n21 2019;27(2):257-65.\n22 6 Collins JE, Neogi T, Losina E. Trajectories of structural disease progression in knee\n23 osteoarthritis. Arthritis Care Res (Hoboken) 2021;73(9):1354-62.\n24\n7 Zhang W, Sun G, Aitken D, et al. Lysophosphatidylcholines to phosphatidylcholines ratio\n25\npredicts advanced knee osteoarthritis. Rheumatology (Oxford) 2016;55(9):1566-74.\n26\n8 Zhang W, Sun G, Likhodii S, et al. Metabolomic analysis of human plasma reveals that\n27\narginine is depleted in knee osteoarthritis patients. Osteoarthritis Cartilage 2016;24(5):827-\n28\n29 34.\n30 9 Zheng K, Shen N, Chen H, et al. Global and targeted metabolomics of synovial fluid\n31 discovers special osteoarthritis metabolites. J Orthop Res 2017;35(9):1973-81.\n32\n10 Zhai G, Pelletier JP, Liu M, et al. Activation of the phosphatidylcholine to\n33\nlysophosphatidylcholine pathway is associated with osteoarthritis knee cartilage volume loss\n34\nover time. Sci Rep 2019;9(1):9648.\n35\n36 11 Tootsi K, Vilba K, Märtson A, Kals J, Paapstel K, Zilmer M. Metabolomic signature of\n37 amino acids, biogenic amines and lipids in blood serum of patients with severe osteoarthritis.\n38 Metabolites 2020;10(8).\n39 12 Sasaki E, Yamamoto H, Asari T, et al. Metabolomics with severity of radiographic knee\n40\nosteoarthritis and early phase synovitis in middle-aged women from the Iwaki Health\n41\nPromotion Project: a cross-sectional study. Arthritis Res Ther 2022;24(1):145.\n42\n13 Xie Z, Aitken D, Liu M, et al. Serum metabolomic signatures for knee cartilage volume loss\n43\n44 over 10 years in community-dwelling older adults. Life (Basel) 2022;12(6).\n45 14 Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent Reporting of a multivariable\n46 prediction model for Individual Prognosis Or Diagnosis (TRIPOD): the TRIPOD Statement.\n47\nBr J Surg 2015;102(3):148-58.\n48\n15 Zhai G, Cicuttini F, Srikanth V, Cooley H, Ding C, Jones G. Factors associated with hip\n49\ncartilage volume measured by magnetic resonance imaging: the Tasmanian Older Adult\n50\nCohort Study. Arthritis Rheum 2005;52(4):1069-76.\n51\n52 16 Khan HI, Aitken D, Zhai G, et al. Association between hip and knee cartilage measured\n53 using radiographs and magnetic resonance imaging: the Tasmanian Older Adult Cohort\n54 Study. Rheumatology (Oxford) 2013;52(11):2009-15.\n55\n56\n57\n58\n59 21\n60\nDownloaded\nfrom\nhttps://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keaf686/8402357\nby\nUniversiteitsbibliotheek\nUtrecht\nuser\non\n24\nDecember\n2025\n\n--- PAGE 22 ---\nRheumatology Page 22 of 107\nRheumatology RHE-25-2165.R1\n1\n2\n3 17 Raynauld JP, Martel-Pelletier J, Bias P, et al. Protective effects of licofelone, a 5-\n4\nlipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee\n5\nosteoarthritis: a first multicentre clinical trial using quantitative MRI. Ann Rheum Dis\n6\n2009;68(6):938-47.\n7\n8 18 Pan F, Liu M, Randell EW, Rahman P, Jones G, Zhai G. Sphingomyelin is involved in\n9 multisite musculoskeletal pain: evidence from metabolomic analysis in 2 independent\n10 cohorts. Pain 2021;162(6):1876-81.\n11\n19 Zhai G, Pelletier JP, Liu M, Randell EW, Rahman P, Martel-Pelletier J. Serum\n12\nlysophosphatidylcholines to phosphatidylcholines ratio is associated with symptomatic\n13\nresponders to symptomatic drugs in knee osteoarthritis patients. Arthritis Res Ther\n14\n2019;21(1):224.\n15\n16 20 Jamshidi A, Leclercq M, Labbe A, et al. Identification of the most important features of knee\n17 osteoarthritis structural progressors using machine learning methods. Ther Adv\n18 Musculoskelet Dis 2020;12:1-12.\n19\n21 Bonakdari H, Jamshidi A, Pelletier JP, Abram F, Tardif G, Martel-Pelletier J. A warning\n20\nmachine learning algorithm for early knee osteoarthritis structural progressor patient\n21\nscreening. Ther Adv Musculoskel Dis 2021;13:1-16.\n22\n23 22 Bonakdari H, Pelletier JP, Blanco F, et al. Single nucleotide polymorphism genes and\n24 mitochondrial DNA haplogroups as biomarkers for early prediction of knee osteoarthritis\n25 structural progressors: use of supervised machine learning classifiers. BMC Med\n26 2022;20:316.\n27\n23 Nyamundanda G, Gormley IC, Fan Y, Gallagher WM, Brennan L. MetSizeR: selecting the\n28\noptimal sample size for metabolomic studies using an analysis based approach. BMC\n29\nBioinformatics 2013;14:338.\n30\n31 24 Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating\n32 characteristic (ROC) curve. Radiology 1982;143(1):29-36.\n33 25 National Center for Biotechnology Information (US) INB. Diagnostic Test Accuracy:\n34\nMeasures and Interpretation. (n.d.). Appendix E: Formulas for Accuracy. . In.\n35\n26 Hannan MT, Felson DT, Pincus T. Analysis of the discordance between radiographic\n36\nchanges and knee pain in osteoarthritis of the knee. J Rheumatol 2000;27(6):1513-7.\n37\n27 Raynauld JP, Martel-Pelletier J, Berthiaume MJ, et al. Quantitative magnetic resonance\n38\n39 imaging evaluation of knee osteoarthritis progression over two years and correlation with\n40 clinical symptoms and radiologic changes. Arthritis Rheum 2004;50:476-87.\n41 28 Mobasheri A, van Spil WE, Budd E, et al. Molecular taxonomy of osteoarthritis for patient\n42\nstratification, disease management and drug development: biochemical markers associated\n43\nwith emerging clinical phenotypes and molecular endotypes. Curr Opin Rheumatol\n44\n2019;31(1):80-9.\n45\n46 29 Angelini F, Widera P, Mobasheri A, et al. Osteoarthritis endotype discovery via clustering\n47 of biochemical marker data. Ann Rheum Dis 2022;81(5):666-75.\n48 30 Guijas C, Montenegro-Burke JR, Warth B, Spilker ME, Siuzdak G. Metabolomics activity\n49 screening for identifying metabolites that modulate phenotype. Nat Biotechnol\n50\n2018;36(4):316-20.\n51\n31 Zhai G, Randell EW, Rahman P. Metabolomics of osteoarthritis: emerging novel markers\n52\nand their potential clinical utility. Rheumatology (Oxford) 2018;57(12):2087-95.\n53\n54 32 Zhai G. The role of metabolomics in precision medicine of osteoarthritis: How far are we?\n55 Osteoarthritis and Cartilage Open 2021;3(4):100170.\n56\n57\n58\n59 22\n60\nDownloaded\nfrom\nhttps://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keaf686/8402357\nby\nUniversiteitsbibliotheek\nUtrecht\nuser\non\n24\nDecember\n2025\n\n--- PAGE 23 ---\nPage 23 of 107 Rheumatology\nRheumatology RHE-25-2165.R1\n1\n2\n3 33 Guan M, Yu Q, Zhou G, et al. Mechanisms of chondrocyte cell death in osteoarthritis:\n4\nimplications for disease progression and treatment. J Orthop Surg Res 2024;19(1):550.\n5\n34 Steinmeyer J. P",
  "Article 3: Physical Activity and Joint Space Loss": "\n--- PAGE 1 ---\nCopyright © 2025 The Author(s). Published by The Journal of Bone and Joint Surgery, Inc.\nSCIENTIFIC ARTICLES\nOBSERVATIONAL STUDIES\nPhysical Activity and 4-Year Radiographic\nMedial Joint Space Loss in Knee Osteoarthritis\nE\nA Joint Model Analysis\nQianying Cai, PhD*, Hao Peng, MD*, Vicky Duong, PhD, Win Min Oo, PhD, Youshui Gao, P\nL\nhD, Yong Feng, PhD,\nChangqing Zhang, PhD, Liubov Arbeeva, PhD, Daniel K. White, PhD, David J. Hunter, PhD, and Kai Fu, PhD\nC\nBackground: We examined the association between physical activity (PA) and joint space loss (JSL) over 48 months in individuals\nwith knee osteoarthritis to assess the role of the PA level in knee osteoarthritis progreIssion.\nMethods: We analyzed 1,806 participants from the Osteoarthritis Initiative. PA\nT\nwas measured with the Physical Activity Scale\nfor the Elderly (PASE) and was categorized as low, moderate, or high. JSL was defined as a reduction in joint space width of\n‡0.7 mm. Analyses were stratified by the baseline Kellgren-LawrenRce (KL) grade. Cox proportional-hazards (CoxPH) and\njoint models assessed the association between baseline PA and changes in longitudinal PA and JSL, adjusting for\ncovariates.\nResults: Over 48 months, 33.8% of the patients experienced AJSL. In patients with KL grade 2, the moderate PA tertile was\nassociated with a reduced JSL risk compared with low PA in both standard and marginal CoxPH analyses. However, in patients\nwith KL grade 3, increasing PA in the continuous PASE modeling was associated with increased JSL risk (marginal CoxPH: hazard\nratio [HR], 1.002 [95% confidence interval (CI), 1.001 to 1.004] ), confirmed by joint models (HR, 1.083 [95% CI, 1.020 to 1.150]). The\nrate of change of PA over time did not significantly Sinfluence progression.\nConclusions: Moderate or high PA did not increase the 4-year JSL risk in patients with KL grade 2. However, higher\ncurrent PA was associated with higher JSSL risk in patients with KL grade 3, highlighting the need for further research\non the complex impact of PA on osteoarthritis. These fi ndings may help clinicians to identify patient subgroups who\ncould bene fi t from tailored PA recommendations, informing va lue-based care and personalized osteoarthritis\nmanagement. E\nLevel of Evidence: Prognostic Level III. See Instructions for Authors for a complete description of levels of evidence.\nR\nO\nsteoarthritis is a prevalent chronic joint disease that tions such as joint space narrowing and osteophyte forma-\nP\naffects approximately 600 million people world- tion provide reliable markers of structural damage to the\nwide 1,2 . The knee is the most commonly affected joint in osteoarthritis, and thus play a crucial role in as-\njoint, accounting- for about 85% of the substantial global sessing the structural damage of knee osteoarthritis. Joint\nosteoarthritis burden 3 . Characteristic radiographic altera- space loss (JSL), a measure of worsening joint space\nN\n*Qianying Cai, PhD, and Hao Peng, MD, contributed equally to this work.\nI\nDisclosure: This study was funded by the Shanghai Sixth People’s Hospital Clinical Research Project (ynhg202501), the National Natural Science\nFoundation of China (Grant No. 82404338),the Shanghai Municipal Education Commission—Gaofeng Clinical Medicine Grant (2022), the Shanghai\nMunicipal Health Commission Health Industry Clinical Research Project (Grant 20224Y0139), and the Shanghai Shen Kang Hospital Development\nCentre, Data Sharing and Duplicated RCTs in Clinical Research (Grant SHDC2024CRI091). The Disclosure of Potential Conflicts of Interest forms are\nprovided with the online version of the article (http://links.lww.com/JBJS/I978).\nDisclaimer: This manuscript was prepared using an Osteoarthritis Initiative (OAI) public use data set and does not necessarily reflect the opinions or\nviews of the OAI Study Investigators, the National Institutes of Health (NIH), or the private funding partners.\nCopyright © 2025 The Author(s). Published by The Journal of Bone and Joint Surgery, Incorporated. This is an open access article distributed under the\nterms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share\nthe work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.\n(cid:129) (cid:129)\nJ Bone Joint Surg Am. 2025 Dec 3 0(0): 1-8 http://dx.doi.org/10.2106/JBJS.25.00656\n1\n\n--- PAGE 2 ---\nPhysical Activity and 4-Year Radiographic Medial Joint Space Loss in\nKnee Osteoarthritis\nnarrowing, indicates the structural progression in knee are associated with radiographic JSL in the RKOA\nosteoarthritis and has been recognized as a sensitive pre- population over 48 months.\ndictor of clinical outcomes such as knee surgery and knee\nreplacement 4-6 . Materials and Methods\nPhysical activity (PA) in the Data Source and Study\nform of exercise is strongly rec- Participants\nommended for knee osteoar-\nthritis 7 , offering benefits such as This longitudinal cohort study\nW\n4\ne\n8 -\nu\nm\nti\no\nliz\nn\ne\nth\nd data\nf\nf\no\nro\nll\nm\now -\nt\nu\nh\np\ne\np\np\na\nh\ni\ny\nn\ns ic\na\na\nl\nl\nl e\nfu\nv\nn\nia\nc\nt\nt\ni\ni\no\no\nn\nn , m\nan\na\nd\nin l\ni\ny\nm\nth\np\nr\nr\no\no\nu\nve\ng\nd\nh found that subjects with\nperiod pr\nE\novided by the OAI. We\nexamined data on PA and radi-\npromising conservative manage-\nment strategies 8,9 . Numerous\nmoderate PA had the lowest ogr\nL\naphs and identified 1,806\nparticipants who met the fol-\nstudies have explored the rela-\nrisk of developing JSL and lowing inclusion criteria: (1)\nt\no\ni\ns\no\nt\nn\ne\ns\no\nh\na\ni\nr\np\nt h\nb\nr\ne\nit\nt\ni\nw\ns\ne\np\ne\nr\nn\no g\nP\nre\nA\ns s\na\nio\nn\nn\nd\nu\nk\ns\nn\nin\nee\ng demonstrated an association\nC\nbaseline evidence of RKOA\n(Kellgren-Lawrence [KL] grade\nlarge osteoarthritis cohort data-\nbases such as the Osteoarthritis between higher current PA and of 2 or 3 based on central read-\nIings); (2) recorded Physical\nInitiative (OAI) and the Multi-\nhigher 4-year JSL risk inT Activity Scale for the Elderly\ncenter Osteoarthritis Study\n(MOST) 10-13 . Nevertheless, the patients with a baseline KL\n(\nr\nP\nec\nA\no\nS\nr\nE\nd\n)\ne d\ns c\nm\no\ne\nre\na su\nat\nr e\nb\nm\na\ne\ns\nn\ne\nt\nl\ns\nin\no\ne\nf\n;\nt\n(\nh\n3\ne\n)\nassociation between PA and R\nstructural progression of osteo- grade of 3.\nminimum medial joint space\nwidth (JSW) of ‡0.7 mm at\narthritis remains controversial.\nbaseline, and at least 1 follow-up\nTo date, no study has accounted A\nmeasurement at subsequent\nfor the effects of both time-\nvisits (Fig. 1); and (4) no knee\nvarying PA levels and trends in\nreplacement surgery history.\nPA changes on the incidence of\nAll source data are available from the OAI (https://data-\nJSL during radiographic knee osteoarthritis S(RKOA)\narchive.nimh.nih.gov/oai/). The data from our analyses are\nprogression.\nalso available from us on reasonable request.\nA joint model (JM), which integrates repeated -\nmeasurement data with the timing of sSpeci fi c events,\nmay offer a more rational approach. JMs are increas -\ningly favored in epidemiological research for their\nMeasurements of Time-Varying Exposure, Outcome,\ncapacity to effectively represent\nE\nthe interdependence\nand Baseline Covariates\nand correlation between longitudinal data and time-to - The follow-up design is described in a flowchart in Figure 2. PA\nevent outcomes 14-18 . This study aimed to determine was quantified using the PASE questionnaire, a validated ins-\nR\nwhether self-reported PA and its temporal variations trument that has been used in previous studies 19,20 . The time-\nP\n-\nN\nI\nFig. 1\nMinimum joint space width (mJSW) measurements in the medial and lateral compartments at baseline and follow-up in the OAI. Note that the OAI\nreports mJSW for the medial compartment only. (Image based on the OAI protocol, “Central Assessment of Longitudinal Knee X-rays for Quantitative\nJSW.”)\n2\n\n--- PAGE 3 ---\nThe Journal of Bone & Joint Surgery\nVolume 00 (cid:129) Number 00\nE\nL\nC\nI\nT\nR\nA\nS\nS\nE\nFig. 2\nFlowchartforthis study. OAI = Osteoarthritis Initiative, KR = knee replacement, KL = Kellgren-Lawrence, PASE = Physical Activity Scaleforthe Elderly (range,\nR\n0 to 793), JSW = joint space width, RKOA = radiographic knee osteoarthritis, and JSL = joint space loss.\nto-event outcome, definitive radiographic JSL, was defined the more painful side; or if still equal, the side with the lower\nP\naccording to the Foundation for the National Institutes of baseline JSW).\nHealth Osteoarthritis Biomarkers Project as a decrease of\n‡0.7 mm in minim-um medial JSW measurements (Fig. 1) in at Statistical Analysis\nleast 1 knee between baseline and follow-up 4 . Participants We summarized the cohort characteristics using counts and\nwere follo\nN\nwed until JSL, knee replacement, loss to follow-up, percentages for categorical variables and using means and\ntheir final visit, or 48 months. For patients with knee standard deviations for continuous variables. The proportional-\nreplacement between 12 and 48 months, JSL status was based hazards (PH) assumption was tested using Schoenfeld res-\non pre\nI\noperative data. iduals, and the linearity of the continuous PASE score was\nBaseline covariates included age, gender, race, body evaluated with Martingale residuals. Given the apparent viola-\nmass index (BMI), knee pain, KL grade, knee alignment tion of both the PH and linearity assumptions for the PASE\n(measured as the mechanical hip-knee-ankle angle on score, PA levels were categorized into tertiles according to the\nstandardized long-limb radiographs, and classified as neu- baseline PASE score (range, 0 to 793): low, £112; moderate,\ntral [2 2° to 12°], varus [<2 2°], or valgus [>12°] 21 ), bilateral 113 to 184; and high, ‡185. A significant PA · KL grade interac-\nor unilateral knee involvement, and comorbidity status tion (p = 0.005) prompted stratified Cox proportional-hazards\n(Charlson Comorbidity Index [CCI], 0 compared with >0 22 ). (CoxPH) analyses by baseline KL grade.\nKnee pain level was evaluated using the Western Ontario We applied 2 types of CoxPH models to examine the\nand McMaster Universities Osteoarthritis (WOMAC) Index association between the baseline PA and the JSL risk. First, a\npain scale (0 to 20) 23 . We selected the index knee as the knee Cox model with a cluster term was used to account for\nwith greater baseline severity (higher KL grade; or if equal, within-subject correlations (marginal Cox model). Second, a\n3\n\n--- PAGE 4 ---\nPhysical Activity and 4-Year Radiographic Medial Joint Space Loss in\nKnee Osteoarthritis\nmarginal CoxPH model was fitted using a penalized cubic PASE scale and of its change with the risk of JSL. The modeling\nspline for the PASE measurements to test for nonlinear incorporated 2 sub-models: a longitudinal sub-model (linear\nassociations with JSL. mixed-effects model) for longitudinal repeated measures with\nFurthermore, we performed joint modeling to explore the normally distributed errors, and a survival sub-model (CoxPH\nassociation of longitudinally measured PA on the continuous model) that specified the hazard of outcome event1 4,18.\nTable 1. Data for the Participants Included in the Analyses (N = 1,806)*\nE\nOverall (N = 1,806) KL Grade 2 (N = 1,006) KL Grade 3 (N = 800)\nBaseline L\nAge (yr) 62.15 ± 8.89 60.84 ± 8.70 63.80 ± 8.87\nFemale gender 1,110 (61.5%) 661 (65.7%) 449 (56.1%)\nC\nWhite race 1,365 (75.6%) 752 (74.8%) 613 (76.6%)\nNo. of patients missing data 1 (0.1%) 1 (0.1%) 0 (0.0%)\nBMI (kg/m2 ) 29.87 ± 4.91 29.57 ± 4.91 30.26 ± 4.89\nI\nNo. of patients missing data 3 (0.2%) 2 (0.2%) 1 (0.1%)\nT\nCCI grade\n0 1,305 (72.3%) 753 (74.9%) 552 (69.0%)\n>0 479 (26.5%) R241 (24.0%) 238 (29.8%)\nNo. of patients missing data 22 (1.2%) 12 (1.2%) 10 (1.2%)\nWOMAC pain 3.80 ± 3.93 3.55 ± 3.92 4.12 ± 3.92\n2 sides involved 1,141 (63.2%) A564 (56.1%) 577 (72.1%)\nKnee alignment\nNeutral 482 (26.7%) 276 (27.4%) 206 (25.8%)\nVarus 494 (27.4% ) 229 (22.8%) 265 (33.1%)\nValgus 8S21 (45.5%) 493 (49.0%) 328 (41.0%)\nNo. of patients missing data 9 (0.5%) 8 (0.8%) 1 (0.1%)\nJSW 3.87 ± 1.34 4.45 ± 0.96 3.15 ± 1.40\nPASE S157.37 ± 82.18 159.57 ± 83.59 154.59 ± 80.34\nLeisure activities 29.42 ± 30.84 30.05 ± 30.47 28.64 ± 31.30\nHousehold activity 84.24 ± 39.73 83.56 ± 39.63 85.11 ± 39.87\nOccupational activity\nE\n43.70 ± 59.44 45.97 ± 60.03 40.84 ± 58.61\nPASE physical activity level tertiles\nLow (£112) 601 (33.3%) 323 (32.1%) 278 (34.8%)\nR\nModerate (113 to 184) 597 (33.1%) 334 (33.2%) 263 (32.9%)\nHigh (‡185) 608 (33.7%) 349 (34.7%) 259 (32.4%)\nLongitudinal mePasurements\nFollow-up (yr) 3.20 ± 1.12 3.33 ± 1.07 3.04 ± 1.16\nJoint space loss 610 (33.8%) 281 (27.9%) 329 (41.1%)\nKnee rep-lacement 42 (2.3%) 12 (1.2%) 30 (3.8%)\nPASE at 12 months 152.69 ± 81.00 157.12 ± 82.34 146.73 ± 78.83\nN\nLeisure activities 26.42 ± 29.96 27.08 ± 30.18 25.53 ± 29.66\nHousehold activity 83.49 ± 40.28 83.09 ± 40.58 84.03 ± 39.90\nOccupational activity 42.78 ± 58.19 46.95 ± 60.30 37.17 ± 54.78\nI\nPASE at 24 months 151.47 ± 81.63 155.83 ± 83.30 145.24 ± 78.85\nLeisure activities 26.17 ± 27.61 26.02 ± 27.18 26.39 ± 28.24\nHousehold activity 83.32 ± 40.10 83.82 ± 40.09 82.60 ± 40.13\nOccupational activity 41.98 ± 60.54 45.99 ± 62.91 36.25 ± 56.55\nPASE at 36 months 145.30 ± 80.35 145.53 ± 80.37 144.92 ± 80.43\nLeisure activities 23.98 ± 25.14 24.48 ± 25.89 23.14 ± 23.85\nHousehold activity 80.13 ± 40.86 79.14 ± 40.53 81.77 ± 41.40\nOccupational activity 41.19 ± 58.77 41.90 ± 58.77 40.01 ± 58.82\n*The values are given as either the mean and the standard deviation or the number of patients with the percentage in parentheses. CCI =\nCharlson Comorbidity Index (range, 0 to 33), WOMAC pain = Western Ontario and McMaster Universities Osteoarthritis Index pain (range, 0 to 20),\nJSW = joint space width, and PASE = Physical Activity Scale for the Elderly (range, 0 to 793).\n4\n\n--- PAGE 5 ---\nThe Journal of Bone & Joint Surgery\nVolume 00 (cid:129) Number 00\nSpecifically, we fitted 3 JMs: (1) the current-level model (JM1) In individuals with KL grade 2, the lowest estimated\nassumed that the risk of JSL depends solely on the current JSL incidence was found in those with moderate PA levels\nPA; (2) the slope model (JM2) assumed that the risk depends (23.0% [95% CI, 18.0% to 27.8%]). In contrast, among sub-\nsolely on the slope of the true PA trajectory at a given time; jects with KL grade 3, the lowest estimated incidence was\nand (3) the combined model (JM3). To satisfy the assump- found in the low PA group (40.1% [95% CI, 33.7% to 50.2%]),\ntion of normality, a square-root transformation was applied with higher incidences in the moderate PA group (44.0%\nto normalize the PASE score (see Appendix Supplemental [95% CI, 37.0% to 50.2%]) and the high PA group (55.6%\nFig. S1). We compared the JMs using the Bayesian infor- [95% CI, 48.4% to 61.8%]) (see Appendix Supplemental\nmation criterion (BIC), for which lower values indicate a Table S1). E\nbetter fit.\nWe also performed sensitivity analyses using multiple\nAssociation Analyses Using Standard and Marginal\nimputation (5 data sets via MICE [multivariate imputation by\nCoxPH Models\nL\nchained equations], with predictive mean matching for BMI\nW\nan\ne\nd l\na\no\nls\ng\no\nis t\np\nic\ne r\nr\nf\ne\no\ng\nr\nr\nm\nes\ne\ns\nd\ni o\n3\nn\no\nfo\nt\nr\nh e\nC\nr\nC I\ns\n;\ne\np\nn\no\ns\no\nit\nl\ni\ne\nv\nd\nit y\nw i\na\nth\nn a\nR\nly\nu\ns\nb\ne\nin\ns\n’s\nb\nr\ny\nu\nu\nle\ns\ns\nin\n) 2\ng\n4, 25\na\n. T ar h e e p r r e e s s u e l n ts te f d r o in m T t a h b e le s 2 C ta . W nd e a f r o d u a n n d d n o m s a i r g g n in ifi a c l a C n o t x as P s H o c m ia o ti d o e n ls s\ncomposite outcome of JSL and knee replacement, applying a\nbetween the high PA tertile and the risk of radiographic JSL in\nset of 5 previously reported PASE categories (£100, 101 to 140, individuals with a baseline KL grade of 2. This was evidenced\n141 to 180, 181 to 220, >220) 10 , and incorporating a time- in both the standar\nI\nd CoxPH regression analysis (HR, 1.023\nvarying KL grade as a covariate.\n[95% CI, 0.75T9 to 1.380]) and marginal CoxPH regression\nHazard ratios (HRs) with 95% confidence intervals (CIs) analysis (HR, 1.166 [95% CI, 0.861 to 1.579]). Conversely, in\nwere reported, and significance was defined as p < 0.05. All KL g R rade-3 subjects, we found an increased risk of JSL in\nstatistical analyses were conducted using R (version 4.3.4; The\nthose with high PA in both standard CoxPH models (HR,\nR Foundation). The “JM” package was used to fit the joint 1.452 [95% CI, 1.084 to 1.946]) and marginal CoxPH models\nmodel 26 . A (HR, 1.506 [95% CI, 1.128 to 2.011]). The sensitivity analysis\nusing penalized cubic splines in the marginal CoxPH\nResults models also showed a nonlinear association between PASE\nmeasurements and JSL incidence (see Appendix Supple-\nObserved JSL Events and Characteristics\nmental Fig. S3).\nS\nOver the 48 months, we identified 5,534 PA measurements Analyses of the PASE subscales in individuals with\nand 610 incident JSL events during the visits at 12, 24, 36, KL grade 3 revealed possible associations of JSL risk\nand 48 months (see Appendix SupplemenStal Fig. S1). The with the levels of household activity (standard CoxPH\nparticipants with KL grade 2 at baseline had a higher pro- HR, 1.003 [95% CI, 1.001 to 1.006]) and occupational\nportion of females (65.7%) and lower BMI compared with the activity (marginal CoxPH HR, 1.003 [95% CI, 1.001 to\nKL grade-3 group. Furthermore, thEese participants had a 1.005]); however, estimates were small and not consis -\nlonger follow-up, a higher JSW at baseline, and a lower num- tently signi fi cant across models, and we interpreted\nber of incident JSL events (Table 1). them cautiously.\nR\nTable 2. Cox Proportional-Hazards (CoxPH) Regression Analysis for the Association of Physical Activity with the Risk of JSL in RKOA*\nP\nKL Grade 2 KL Grade 3\nPhysical -Activity Standard CoxPH† Marginal CoxPH‡ Standard CoxPH† Marginal CoxPH‡\nN\nPASE, continuous 1.001 (0.999 to 1.002) 1.001 (0.999 to 1.003) 1.001 (1.000 to 1.003) 1.002 (1.001 to 1.004)\nPASE subscales, continuous§\nILeisure activities 1.001 (0.997 to 1.005) 1.002 (0.998 to 1.006) 1.002 (0.999 to 1.006) 1.000 (0.996 to 1.004)\nHousehold activity 1.000 (0.997 to 1.003) 1.001 (0.998 to 1.004) 1.003 (1.001 to 1.006) 1.002 (0.999 to 1.005)\nOccupational activity 1.001 (0.999 to 1.003) 1.001 (0.999 to 1.003) 1.000 (0.998 to 1.002) 1.003 (1.001 to 1.005)\nPASE, by tertiles\nLow (£112) Reference Reference Reference Reference\nModerate (113 to 184) 0.690 (0.503 to 0.947) 0.710 (0.511 to 0.986) 1.370 (1.036 to 1.812) 1.124 (0.845 to 1.495)\nHigh (‡185) 1.023 (0.759 to 1.380) 1.166 (0.861 to 1.579) 1.452 (1.084 to 1.946) 1.506 (1.128 to 2.011)\n*The values are given as the HR, with the 95% CI in parentheses. All models were adjusted for age, sex, BMI, knee alignment, number of involved\njoints (bilateral or unilateral), WOMAC pain score, and CCI grade. †Standard CoxPH models were restricted to baseline PASE measurements.\n‡Marginal CoxPH models incorporated PASE measurements from every visit, with robust standard errors clustered by participant identification\nto account for intrasubject correlation. §Models for the PASE subscales (leisure, household, and occupational) were further adjusted for the\nscores of the other 2 subscales.\n5\n\n--- PAGE 6 ---\nPhysical Activity and 4-Year Radiographic Medial Joint Space Loss in\nKnee Osteoarthritis\nTable 3. Joint Models for the Association of the Longitudinal Total PASE Score and/or Longitudinal Change in PASE Score with the Risk of\nJSL in RKOA*\nKL Grade 2 KL Grade 3\nJoint Model For Current PASE For Slope For Current PASE For Slope\nJM1 1.046 (0.985 to 1.110) NA 1.083 (1.020 to 1.150) NA\nJM2 NA 1.330 (0.359 to 4.931) NA 1.198 (0.332 to 4.327)\nE\nJM3 1.056 (0.994 to 1.122) 0.851 (0.236 to 3.065) 1.086 (1.014 to 1.162) 0.106 (0.004 to 3.097)\n*The values are given as the HR, with the 95% CI in parentheses. In JM1, the survival process depends on the l\nL\nevel of PASE score at the same\ntime point (current level). In JM2, the survival process depends on the slope of the PASE score at the same time point (current slope). In JM3, the\nsurvival process depends on the level of PASE and the slope of PASE at the same time point. Models were adjusted for age, sex, BMI, race, knee\nC\nalignment, number of involved joints (bilateral or unilateral), WOMAC pain, and CCI grade. To satisfy the assumption of normality, a square-root\ntransformation was applied to normalize the longitudinal PASE score. The JMs used settings of method = piecewise-PH-aGH and lng.in.kn = 4,\nand resulted inthefollowingBICs. For KL grade 3, JM1: 10,956; JM2: 10,959, JM3: 9,604. For KL grade 2, JM1: 15,684, JM2: 15,683, JM3: 15,692. PASE\n= Physical Activity Scale for the Elderly (range: 0 to 793), JSL = joint space loss, RKOA = radiographic kInee osteoarthritis, KL = Kellgren-Lawrence, JM\n= joint model, and NA = not applicable.\nT\nAssociation Analysis Using JMs HowRever, the size of this association was small; a 1-unit\nAs in the CoxPH models, no association was revealed by\nincrease in the square root of the PASE score corresponded to\nany model in KL grade-2 subjects (Table 3). For individuals\nan 8.6% rise in the hazard of JSL. Importantly, a high current\nwith KL grade 3, JM1 revealed an association between the\nAPA level, defined as the tertile with a PASE score of ‡185,\ncurrent level of PA and the risk of JSL progression (HR,\nincreased the hazard of JSL incidence by 45.2% (compared\n1.083 [95% CI, 1.020 to 1.150]) (Table 3). In contrast, JM2\nwith low PA).\nshowed that changes in the PA slope did not affect the ris k\nOur findings support prior evidence linking high PA to\n(HR, 1.198 [95% CI, 0.332 to 4.327]). JM3 confir S med the greater structural progression, as they showed a 45% higher\nassociation of the current PA level with JSL occurrence\nJSL risk in KL grade-3 participants with a high PASE level\n(HR, 1.086 [95% CI, 1.014 to 1.162]), and the PA slope again\n(‡185) compared with a low PASE level (£112). These cate-\ndid not show a significant association wit S h JSL risk (HR, gories correspond roughly to mild activity (£112; casual\n0.106 [95% CI, 0.004 to 3.097]). JMs that included the\nwalking or light chores), moderate activity (113 to 184; brisk\ni\ne\nn\ns\nt\nt\ne\nim\nra\na\nc\nt\nt\ne\nio\nd\nn\na\nt\ns\ne\ns\nr\no\nm\nc i\nr\na\ne\nti\nv\no\ne\nn\na l\nf\ne\nr\nd\no m\nsi m\nJM\nila\n3\nr\n,\nr\nw\neE\nh\nsu\nic\nlt\nh\ns .\nh\nW\nad\ne\nt\ns\nh\ne\ne\nle\ns\nc\nm\nte\na\nd\nl l\nt\ne\nh\ns\ne\nt\nw\nda\na\ny\nlk\n);\ni\na\nn\nn\ng\nd\no\nh\nr\ni g\nc\nh\ny c\no\nl\nr\nin\ns\ng\ntr\n;\ne\na\nn\np\nu\np\no\nro\nus\nx i\na\nm\nc\na\nti\nt\nv\ne\nit\nly\ny (\n6\n‡\n,\n1\n0\n8\n0\n5\n0\n; jo\nto\ng g\n9\ni\n,\nn\n0\ng\n0\n,\n0\nfa s\ns\nt\nt e\nc\np\nyc\ns\nli\np\nn\ne\ng\nr\n,\nBIC (Table 3).\nheavy labor; approximately ‡10,000 steps per day), although it\nshould be acknowledged that the PASE is not a direct step-\nR\nSensitivity Analyses\ncount measure.\nOur findings shed some light on the contentious role\nPooled results from the multivariable association analyses of PA in RKOA progression. Conflicting results from previ-\nacross 5 imputed dat\nP\na sets were similar and consistent (see\nous studies may stem from the time-varying nature of PA\nAppendix Supplemental Tables S2 and S3). When using a levels 10,12,27-30 . Most research has considered PA at baseline\ncomposite of JSL - and knee replacement surgery as the out- or at a specific visit time, without accounting for dynamic\ncome, the results again remained stable (see Appendix Sup- changes over subsequent follow-up periods 12,13,21,27,30 . More\nplementaNl Tables S4 and S5). The results of sensitivity analysis\nimportantly, in a chronic disease context, dependency\nusing the previously reported PASE score categories (5 levels)\nbetween time-to-event outcomes and longitudinal trajec-\nfor both standard and marginal CoxPH models also revealed a tories is inherent 14 . We found that it is not a particular PA\npositivIe association between high PA (PASE score of >220)\nlevel with early-stage (KL grade 2) RKOA but rather a high\nand JSL in patients with KL grade 3 (see Appendix Supple-\nPA level in later-stage (KL grade 3) disease that elevates\nmental Table S6). In the sensitivity analysis incorporating the the risk of JSL incidence. This association was confirmed by\ndynamic KL grade as a time-varying covariate, the findings\nthe JM analysis.\nwere consistent with the primary analysis of the subgroup\nThe discrepancy between the outcomes assessed in\nwith a baseline KL grade of 3 (see Appendix Supplemental\nour study and in previous studies of the same cohort might\nTable S7). explain the inconsistencies in the study findings. In our\nstudy, JSL was based on a strict threshold, requiring a\nDiscussion\ndecrease of ‡0.7 mm in minimum medial JSW between\nThis longitudinal cohort study found that subjects with baseline and follow-up measurements, which has been\nmoderate PA had the lowest risk of developing JSL and identified as the cutoff value for maximizing sensitivity and\ndemonstrated an association between higher current PA and specificity in predicting knee surgery over a period of 3\nhigher 4-year JSL risk in patients with a baseline KL grade of 3. years 5 . Hu et al. defined worsening joint space narrowing\n6\n\n--- PAGE 7 ---\nThe Journal of Bone & Joint Surgery\nVolume 00 (cid:129) Number 00\nas an increase in the OARSI (Osteoarthritis Research could merit earlier escalation, although this is pending pro-\nSociety International) joint space narrowing grade (0 to 3) spective confirmation.\nbetween baseline and follow-up 10 . Bricca et al. measured\nthe mean cartilage thickness change over 4 years, showing\nthat magnetic resonance imaging (MRI) was more sensi- Appendix\ntive than JSL seen on radiographs for detecting progres-\nSupporting material provided by the authors is posted\nsion, although limited MRI data reduced the statistical\nwith the online version of this article as a data supple-\npower 28 . ment at jbjs.org (http://links.lww.com/JBJS/I979). n\nOur study still had several limitations. First, PA levels E\nwere evaluated using the self-reported PASE scale, which NOTE: The Osteoarthritis Initiative (OAI) is a public-private partnership conducted by the OAI Study\ncould have introduced recall bias and misclassification bias3 1 . Investigators. Public funding consisted of 5 grants (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-\nThe PASE score can be challenging to convey to the general\n2260; N01-AR-2-2261; N01-AR-2-2262) from the\nL\nNational Institutes of Health, a branch of the\nDepartment of Health and Human Services. Private funding partners include Merck Research\npublic, as its clinical implications are not straightforward. Laboratories, Novartis Pharmaceuticals Corporation, GlaxoSmithKline, and Pfizer, Inc. Private\nS\nra\ne\nd\nc\ni\no\no\nn\ng\nd\nra\n,\np\nth\nh\ne\ns,\np\na\nr\nn\no\nd\ng r\nt\ne\nh\ns\ne\ns io\nli\nn\nm i\no\nta\nf\nt\no\nio\ns\nn\nte\ns\no a\no\nr\nf\nth\nth\nri\ne\nti s\nr a\nw\nd\na\nio\ns\ng\na\nra\ns\np\nse\nh\ns\nic\ns e\nm\nd\ne\no\na\nn\n-\ns\na\ne\nu\nc\nth\nto\no\nr\nr s\nfu\nt\nn\nh\nd\na\ni\nn\nn\nk\ng\na\nfo\nll\nr\nt h\nth\ne\ne\np\nO\nar\nA\nti\nI\nc\ni\ni\ns\np\nm\nan\na\nt\nn\ns\na\nw\ng\nh\ne C\no\nd\nw\nby\ne r\nth\ne\ne\nin\nF\nv\no\no\nu\nlv\nn\ne\nd\nd\na t\ni\ni\nn\no n\nth\nf\ne\no r\nO\nth\nA\ne\nI s\nN\ntu\na\nd\ntio\ny.\nnal Institutes of Health. The\nsurements constrained our analysis of other important oste-\noarthritis progression markers, such as MRI-detected\nI\ncartilage thickness loss. We utilized data on the minimum\nQianying Cai, PhTD1 ,2\nmedial JSW, which could have potentially excluded patients Hao Peng, MD 1\nwith primarily lateral joint disease, despite adjusting for joint Vicky Duong, PhD3\nalignment in our study. Finally, the confounders identified for Win MRin Oo, PhD 3,4\nPA and JSW were limited because of the study’s observational Youshui Gao, PhD 1\nnature, likely leading to an underestimation of confounding\nYong Feng, PhD 1\nChangqing Zhang, PhD 1\nbias. The OAI provided repeated measures of potential time- A\nLiubov Arbeeva, PhD 5\nvarying covariates such as WOMAC pain and BMI. However, Daniel K. White, PhD 6\nwe did not include these covariates directly in our regression David J. Hunter, PhD 3\nmodels because that might have adjusted potential mediator s Kai Fu, PhD1\nand introduced collider bias. Instead, we incorporateSd a set of\nbaseline covariates that affected both PA and JSL, as reported 1 Department of Orthopedic Surgery, Shanghai Sixth People’s Hospital Affiliated\nin prior studies 10,21,28 .\nto Shanghai Jiao Tong University School of Medicine, Shanghai, People’s\nRepublic of China\nIn conclusion, our results found that indSividuals with KL\ngrade-2 RKOA and moderate PA levels (113 to 184; brisk walking 2 Shanghai Institute of Microsurgery on Extremities, Shanghai Sixth People’s\nor cycling; approximately 6,000 to 9,000 steps per day) had the Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,\nlowest JSL incidence. In contrast, thos E e individuals with higher Shanghai, People’s Republic of China\ncurrent PA levels (‡185; jogging, fast cycling, heavy labor;\napproximately ‡10,000 steps per day) may have an increased 3 Kolling Institute, Sydney Musculoskeletal Health, The University of Sydney,\nR Sydney, Australia\nrisk of radiographic progression of osteoarthritis if they have\nreached KL grade 3. In addition, the rate of PA change was not 4 Department of Physical Medicine and Rehabilitation, Mandalay General\nassociated with radiographic progression. These results indi- Hospital, University of Medicine Mandalay, Mandalay, Myanmar\nP\ncate association only, and should not be construed as advice to\nreduce activity by patients with KL grade-3 knee osteoarthritis. 5 Thurston Arthritis Research Center, University of North Carolina at Chapel\nCounseling should- prioritize overall health and function while\nHill, Chapel Hill, North Carolina\nacknowledging potential biological, genetic, and environmental\nconfound N ing. At a systems level, the findings may inform value- 6 Department of Physical Therapy, University of Delaware, Newark, Delaware\nbased care by flagging individuals with advanced disease who Email for corresponding author: kaifu@sjtu.edu.cn\nI\nReferences\n1. GBD 2021 Osteoarthritis Collaborators. Global, regional, and national burden 5. Bruyere O, Richy F, Reginster JY. Three year joint space narrowing predicts\nof osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for long term incidence of knee surgery in patients with osteoarthritis: an eight\nthe Global Burden of Disease Study 2021. Lancet Rheumatol. 2023 Aug 21; year prospective follow up study. Ann Rheum Dis. 2005 Dec;64(12):\n5(9):e508-22. 1727-30.\n2. Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019 Apr 27;393(10182): 6. Hunter D, Nevitt M, Lynch J, Kraus VB, Katz JN, Collins JE, Bowes M, Guermazi\n1745-59. A, Roemer FW, Losina E; FNIH OA Biomarkers Consortium. Longitudinal vali-\n3. Leifer VP, Katz JN, Losina E. The burden of OA-health services and economics. dation of periarticular bone area and 3D shape as biomarkers for knee OA\nOsteoarthritis Cartilage. 2022 Jan;30(1):10-6. progression? Data from the FNIH OA Biomarkers Consortium. Ann Rheum Dis.\n4. Eckstein F, Collins JE, Nevitt MC, Lynch JA, Kraus VB, Katz JN, Losina E, Wirth W, 2016 Sep;75(9):1607-14.\nGuermazi A, Roemer FW, Hunter DJ; FNIH OA Biomarkers Consortium. Brief 7. Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, Callahan L,\nreport: cartilage thickness change as an imaging biomarker of knee osteoarthritis Copenhaver C, Dodge C, Felson D, Gellar K, Harvey WF, Hawker G, Herzig E,\nprogression: data from the Foundation for the National Institutes of Health Oste- Kwoh CK, Nelson AE, Samuels J, Scanzello C, White D, Wise B, Altman RD,\noarthritis Biomarkers Consortium. Arthritis Rheumatol. 2015 Dec;67(12):3184-9. DiRenzo D, Fontanarosa J, Giradi G, Ishimori M, Misra D, Shah AA, Shmagel AK,\n7\n\n--- PAGE 8 ---\nPhysical Activity and 4-Year Radiographic Medial Joint Space Loss in\nKnee Osteoarthritis\nThoma LM, Turgunbaev M, Turner AS, Reston J. 2019 American College of 20. Martin KA, Rejeski WJ, Miller ME, James MK, Ettinger WH Jr, Messier SP.\nRheumatology/Arthritis Foundation Guideline for the Management of Osteo- Validation of the PASE in older adults with knee pain and physical disability.\narthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). 2020 Feb; Med Sci Sports Exerc. 1999 May;31(5):627-33.\n72(2):149-62. 21. Felson DT, Niu J, Yang T, Torner J, Lewis CE, Aliabadi P, Sack B, Sharma L,\n8. Burini RC, Anderson E, Durstine JL, Carson JA. Inflammation, physical activity, Guermazi A, Goggins J, Nevitt MC; MOST and OAI investigators. Physical\nand chronic disease: an evolutionary perspective. Sports Med Health Sci. activity, alignment and knee osteoarthritis: data from MOST and the OAI.\n2020 Mar 26;2(1):1-6. Osteoarthritis Cartilage. 2013 Jun;21(6):789-95.\n9. Duong V, Oo WM, Ding C, Culvenor AG, Hunter DJ. Evaluation and treatment of 22. Wang C, Zhang X, Li B, Mu D. A study of factors impacting disease based on the\nknee pain: a review. JAMA. 2023 Oct 24;330(16):1568-80. Charlson Comorbidity Index in UK Biobank. Front Public Health. 2023 Jan 9;10:\n10. Hu B, Han D, Nevitt MC, Wise BL, Segal NA. Longitudinal relationship between 1050129.\nphysical activity and joint space narrowing: forty-eight-month follow-up data 23. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation\nE\nfrom the Osteoarthritis Initiative. Arthritis Care Res (Hoboken). 2022 Jul;74(7): study of WOMAC: a health status instrument for measuring clinically\n1163-71. important patient relevant outcomes to antirheumatic drug therapy in\n11. Dore´ DA, Winzenberg TM, Ding C, Otahal P, Pelletier JP, Martel-Pelletier J, Cicuttini patients with osteoarthritis of the hip or knee. J Rheumatol. 1988 Dec;15(12):\nFM, Jones G. The association between objectively measured physical activity and 1833-40. L\nknee structural change using MRI. Ann Rheum Dis. 2013 Jul;72(7):1170-5. 24. Zhang Z. Multiple imputation with multivariate imputation by chained equation\n12. Voinier D, Neogi T, Stefanik JJ, Guermazi A, Roemer FW, Thoma LM, Master H, (MICE) package. Ann Transl Med. 2016 Jan;4(2):30.\nNevitt MC, Lewis CE, Torner J, White DK. Using cumulative load to explain how 25. Austin PC, White IR, Lee DCS, van Buuren S. Missing data in clinical research: a\nbody mass index and daily walking relate to worsening knee cartilage damage tutorial on multiple imputation. Can J Cardiol. 2021 Sep;37(9):1322-31.\nover two years: the MOST study. Arthritis Rheumatol. 2020 Jun;72(6):957-65. 26. Dimitris RJM, An R. Package for the joint modelling of longitudinal and time-to-\n13. Schiro` S, Foreman SC, Joseph GB, Souza RB, McCulloch CE, Nevitt MC, Link event data. J Stat Softw. 2010;35(9):1-33.\nTM. Impact of different physical activity types on knee joint structural degen- 27. Kretzschmar M, Lin W I , Nardo L, Joseph GB, Dunlop DD, Heilmeier U, Nevitt\ne\nO\nr\ns\na\nt\nt\ne\nio\no\nn\na r\na\nt\ns\nh\ns\nr\ne\niti\ns\ns\ns\nI\ne\nn\nd\nit i\nw\nat\nit\niv\nh\ne\n3\n.\n-\nS\nT\nk\nM\ne\nR\nle\nI\nt\ni\na\nn\nl\no\nR\nv\na\ne\nd\nr\ni\nw\nol\ne\n.\ni\n2\ng\n0\nh\n2\nt a\n1\nn\nJ\nd\nu l\no\n;5\nb\n0\ne\n(\ns\n7\ne\n): 1\ns\n4\nu\n2\nb\n7\nje\n-4\nc\n0\nts\n.\n: data from the M\nac\nC\nti\n,\nv\nA\nity\nli z\nm\nai\ne\nH\na\nT\ns\n,\nu\nM\nre\ncC\nd\nu\nb\nl\ny\nlo\na\nc\nc\nh\nc\nC\ne\nE\nle\n,\nr\nL\no\ny\nm\nn\ne\nc\nt\nh\ne\nJ\nr,\nA\nk\n,\nn\nL\ne\nin\ne\nk\nj o\nT\ni\nM\nnt\n.\na\nA\nb\ns\nn\ns\no\no\nr\nc\nm\nia\na\nt\nl\ni\ni\no\nti\nn\ne s\no\n,\nf\na\np\nn\nh\nd\ny\nc\nsi\na\nc\nr\na\nti\nl\nl age\n14. Arbeeva L, Nelson AE, Alvarez C, Cleveland RJ, Allen KD, Golightly YM, Jordan T2 measurements obtained from 3T magnetic resonance imaging: data from\nJM, Callahan LF, Schwartz TA. Application of traditional and emerging methods the Osteoarthritis Initiative. Arthritis Care Res (Hoboken). 2015 Sep;67(9):\nfor the joint analysis of repeated measurements with time-to-event outcomes in 12 R 72-80.\nrheumatology. Arthritis Care Res (Hoboken). 2020 May;72(5):615-21.\n28. Bricca A, Wirth W, Juhl CB, Kemnitz J, Hunter DJ, Kwoh CK, Eckstein F, Cul-\n15. Ibrahim JG, Chu H, Chen LM. Basic concepts and methods for joint models of venor AG. Moderate physical activity and prevention of cartilage loss in people\nlongitudinal and survival data. J Clin Oncol. 2010 Jun 1;28(16):2796-801. with knee osteoarthritis: data from the Osteoarthritis Initiative. Arthritis Care\n16. Mchunu NN, Mwambi HG, Rizopoulos D, Reddy T, Yende-Zuma N. Using joint\nA\nRes (Hoboken). 2019 Feb;71(2):218-26.\nmodels to study the association between CD4 count and the risk of death in 29. Kwee RM, Wirth W, Hafezi-Nejad N, Zikria BA, Guermazi A, Demehri S. Role\nTB/HIV data. BMC Med Res Methodol. 2022 Nov 18;22(1):295. of physical activity in cartilage damage progression of subjects with baseline\n17. Rueda-Ochoa OL, Rojas LZ, Ahmad S, van Duijn CM, Ikram MA, Deckers JW , full-thickness cartilage defects in medial tibiofemoral compartment: data\nFranco OH, Rizopoulos D, Kavousi M. Impact of cumulative SBP and serious from the Osteoarthritis Initiative. Osteoarthritis Cartilage. 2016 Nov;24(11):\nadverse events on efficacy of intensive blood pressure treatmen S t: a random- 1898-904.\nized clinical trial. J Hypertens. 2019 May;37(5):1058-69. 30. Lo GH, Musa SM, Driban JB, Kriska AM, McAlindon TE, Souza RB, Petersen NJ,\n18. Asar O¨ , Ritchie J, Kalra PA, Diggle PJ. Joint modelling of repeated measure- Storti KL, Eaton CB, Hochberg MC, Jackson RD, Kwoh CK, Nevitt MC, Suarez-\nment and time-to-event data: an introductory tutorial. IntS J Epidemiol. 2015 Feb; Almazor ME. Running does not increase symptoms or structural progression in\n44(1):334-44. people with knee osteoarthritis: data from the osteoarthritis initiative. Clin\n19. Washburn RA, Smith KW, Jette AM, Janney CA. The Physical Activity Scale for Rheumatol. 2018 Sep;37(9):2497-504.\nthe Elderly (PASE): development and evaluation. J Clin Epidemiol. 1993 Feb; 31. Althubaiti A. Information bias in health research: definition, pitfalls, and\n46(2):153-62. E adjustment methods. J Multidiscip Healthc. 2016 May 4;9:211-7.\nR\nP\n-\nN\nI\n8\n"
}